Drug_ID Indication_name Indication_icd ReferenceID Indication_phase DG01485 Small-cell lung cancer [ICD-11: 2C25] REF00004824 Investigative DG00194 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00004633 Approved DG01826 Bacillary dysentery [ICD-11: 1A02] REF00004586 Approved DG01670 Non-small-cell lung cancer [ICD-11: 2C25] REF00004571 Approved DG01544 Ewing sarcoma [ICD-11: 2B52] REF00004571 . DG01617 Small-cell lung cancer [ICD-11: 2C25] REF00004552 Approved DG01617 Triple negative breast cancer [ICD-11: 2C60-2C6Y] REF00004552 Approved DG01600 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00004552 Investigative DG01582 Malignant mesothelioma [ICD-11: 2C26] REF00004548 Phase 1 DG01582 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004548 Phase 1 DG01582 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004548 Phase 1 DG01546 Nasopharyngeal carcinoma [ICD-11: 2B6B] REF00004546 Phase 2 DG01546 Rectal adenocarcinoma [ICD-11: 2B92] REF00004546 Phase 2 DG01486 Bacterial infection [ICD-11: 1A00-1C4Z] REF00004539 Discontinued in Phase 2 DG01489 Diabetic complication [ICD-11: 5A2Y] REF00004539 Investigative DG01576 Breast cancer [ICD-11: 2C60] REF00004535 Phase 3 DG01576 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004535 Phase 3 DG01819 Hypothalamic hypogonadism [ICD-11: 5A60-5A61] REF00004534 Approved DG01597 Cholangiocarcinoma [ICD-11: 2C12] REF00004532 Phase 2 DG01597 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004532 Phase 2 DG01462 Throat irritation [ICD-11: CA0Z] REF00004525 Investigative DG01533 Breast cancer [ICD-11: 2C60] REF00004523 Phase 2 DG01478 Convulsion [ICD-11: 8A61-8A6Z] REF00004522 Phase 3 DG01493 Bacterial infection [ICD-11: 1A00-1C4Z] REF00004519 Investigative DG01644 Acute myeloid leukaemia [ICD-11: 2A60] REF00004518 Phase 2 DG01818 Central nervous system disease [ICD-11: 8A04-8D87] REF00004515 Approved DG01594 Gastric adenocarcinoma [ICD-11: 2B72] REF00004505 Phase 2/3 DG01594 HER2-positive breast cancer [ICD-11: 2C60-2C6Y] REF00004505 Phase 2/3 DG01618 Non-small-cell lung cancer [ICD-11: 2C25] REF00004501 Phase 1 DG01618 Non-small-cell lung cancer [ICD-11: 2C25] REF00004501 Phase 1 DG01618 Anaplastic large cell lymphoma [ICD-11: 2A90] REF00004501 Phase 1 DG01618 Non-small-cell lung cancer [ICD-11: 2C25] REF00004501 Phase 1 DG01471 Heart arrhythmia [ICD-11: BC65] REF00004496 Approved DG01783 Diabetic complication [ICD-11: 5A2Y] REF00004479 Approved DG01783 Obesity [ICD-11: 5B81] REF00004479 Approved DG01783 Type-2 diabetes [ICD-11: 5A11] REF00004479 Approved DG01531 Cystic fibrosis [ICD-11: CA25] REF00004475 Phase 3 DG01605 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004474 Preclinical DG01494 Multi-drug resistant tuberculosis [ICD-11: MG50-MG52] REF00004467 Phase 2 DG01669 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004467 Phase 3 DG01669 Multiple myeloma [ICD-11: 2A83] REF00004467 Phase 3 DG01494 Mycobacterium infection [ICD-11: 1B10-1B21] REF00004467 Phase 2 DG01831 Breast cancer [ICD-11: 2C60] REF00004457 Phase 1 DG01794 Discovery agent [ICD-11: N.A.] REF00004452 Investigative DG01551 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00004451 Phase 1 DG01551 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00004451 Phase 1 DG01532 Melanoma [ICD-11: 2C30] REF00004450 Phase 3 DG01532 Melanoma [ICD-11: 2C30] REF00004450 Phase 3 DG01532 Ureteral cancer [ICD-11: 2C92] REF00004450 Phase 3 DG01532 Renal cell carcinoma [ICD-11: 2C90] REF00004450 Phase 3 DG01532 Melanoma [ICD-11: 2C30] REF00004450 Phase 3 DG01532 Head and neck cancer [ICD-11: 2D42] REF00004450 Phase 3 DG01532 Breast cancer [ICD-11: 2C60] REF00004450 Phase 3 DG01532 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004450 Phase 3 DG01611 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004445 Investigative DG01611 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004445 Investigative DG01625 Cholangiocarcinoma [ICD-11: 2C12] REF00004439 Approved DG01625 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004439 Approved DG01625 Multiple myeloma [ICD-11: 2A83] REF00004439 Approved DG01525 Psoriasis vulgaris [ICD-11: EA90] REF00004424 Investigative DG01775 Insomnia [ICD-11: 7A00] REF00004417 Approved DG01825 Chronic pain [ICD-11: MG30] REF00004416 Approved DG01778 Pain [ICD-11: MG30] REF00004415 Approved DG01770 Rheumatoid arthritis [ICD-11: FA20] REF00004412 Approved DG01496 Renal cell carcinoma [ICD-11: 2C90] REF00004406 Investigative DG01848 Melanoma [ICD-11: 2C30] REF00004405 Approved DG01595 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004401 Phase 2 DG01595 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004401 Phase 2 DG01626 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] REF00004395 Phase 2 DG01624 Gastrointestinal stromal tumour [ICD-11: 2B5B] REF00004392 Phase 1 DG01624 Glioma [ICD-11: 2A00] REF00004392 Phase 1 DG01624 Systemic mastocytosis [ICD-11: 2A21] REF00004392 Phase 1 DG01624 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004392 Phase 1 DG01570 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004392 Investigative DG01488 Bacterial infection [ICD-11: 1A00-1C4Z] REF00004390 Investigative DG01652 Gastrointestinal stromal tumour [ICD-11: 2B5B] REF00004389 Phase 1 DG01652 Systemic mastocytosis [ICD-11: 2A21] REF00004389 Phase 1 DG01652 Mast cell leukaemia [ICD-11: 2A21] REF00004389 Phase 1 DG01607 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004387 Phase 2 DG01631 Non-small-cell lung cancer [ICD-11: 2C25] REF00004384 Patented DG01631 Non-small-cell lung cancer [ICD-11: 2C25] REF00004384 Patented DG01640 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004375 Phase 1/2 DG01671 Non-hodgkin lymphoma [ICD-11: 2B33] REF00004373 Phase 1 DG01671 Non-hodgkin lymphoma [ICD-11: 2B33] REF00004373 Phase 1 DG01671 Follicular lymphoma [ICD-11: 2A80] REF00004373 Phase 1 DG01535 Bacterial infection [ICD-11: 1A00-1C4Z] REF00004372 Phase 2 DG01529 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00004367 Phase 2 DG01613 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004365 Approved DG01613 Breast cancer [ICD-11: 2C60] REF00004365 Approved DG01502 Ovarian cancer [ICD-11: 2C73] REF00004360 Phase 3 DG01515 Skin infection [ICD-11: 1F28-1G0Z] REF00004360 Phase 3 DG01502 Ovarian cancer [ICD-11: 2C73] REF00004360 Phase 3 DG01604 Discovery agent [ICD-11: N.A.] REF00004359 Investigative DG01547 Basal cell carcinoma [ICD-11: 2C32] REF00004355 Phase 2 DG01547 Basal cell nevus syndrome [ICD-11: 2C32] REF00004355 Phase 2 DG01547 Chondrosarcoma [ICD-11: 2B50] REF00004355 Phase 2 DG01566 Thrombosis [ICD-11: DB61-GB90] REF00004348 Phase 3 DG01803 Malaria [ICD-11: 1F40[ REF00004344 Approved DG01550 Essential thrombocythemia [ICD-11: 3B63] REF00004341 Phase 2 DG01550 Essential thrombocythemia [ICD-11: 3B63] REF00004341 Phase 2 DG01550 Vitiligo [ICD-11: ED63] REF00004341 Phase 2 DG01550 Atopic dermatitis [ICD-11: EA80] REF00004341 Phase 2 DG01592 Breast cancer [ICD-11: 2C60] REF00004341 Phase 1 DG01593 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004341 Approved DG01592 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004341 Phase 1 DG01592 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004341 Phase 1 DG01550 Pancreatic cancer [ICD-11: 2C10] REF00004341 Phase 2 DG01550 High-risk myelofibrosis [ICD-11: 2A20] REF00004341 Phase 2 DG01914 Bacterial infection [ICD-11: 1A00-1C4Z] REF00004341 Phase 2 DG01781 Pain [ICD-11: MG30] REF00004336 Approved DG01781 Anaesthesia [ICD-11: 8E22] REF00004336 Approved DG01653 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004332 Phase 1 DG01588 Melanoma [ICD-11: 2C30] REF00004330 Phase 2 DG01588 Melanoma [ICD-11: 2C30] REF00004330 Phase 2 DG01588 Melanoma [ICD-11: 2C30] REF00004330 Phase 2 DG01463 Alzheimer disease [ICD-11: 8A20] REF00004329 Investigative DG01507 Non-small-cell lung cancer [ICD-11: 2C25] REF00004304 Approved DG01639 Cholangiocarcinoma [ICD-11: 2C12] REF00004297 Phase 1 DG01639 Myeloproliferative syndrome [ICD-11: 2A20] REF00004297 Phase 1 DG01639 Bladder cancer [ICD-11: 2C94] REF00004297 Phase 1 DG01517 Breast cancer [ICD-11: 2C60] REF00004294 Phase 3 DG01552 Lymphoma [ICD-11: 2A90- 2A85] REF00004294 Approved DG01484 Malaria [ICD-11: 1F45] REF00004289 Phase 3 DG01467 Diarrhea [ICD-11: DA90] REF00004288 Phase 1 DG01767 Coronary artery disease [ICD-11: BA8Z] REF00004269 Approved DG01779 Parkinson disease [ICD-11: 8A00] REF00004266 Phase 1 DG01521 Melanoma [ICD-11: 2C30] REF00004258 Discontinued in Phase 3 DG01798 Discovery agent [ICD-11: N.A.] REF00004218 Investigative DG01823 Discovery agent [ICD-11: N.A.] REF00004211 Investigative DG01811 Increase blood pressure [ICD-11: BA04] REF00004204 Approved DG01801 Paroxysmal supraventricular tachycardia [ICD-11: BC81] REF00004202 Approved DG01806 Discovery agent [ICD-11: N.A.] REF00004201 Investigative DG01468 Spasm [ICD-11: MB47] REF00004193 Investigative DG01483 Breast cancer [ICD-11: 2C60] REF00004193 Investigative DG01771 Cystitis [ICD-11: GC00] REF00004192 Approved DG01771 Chronic pain [ICD-11: MG30] REF00004192 Approved DG01619 Renal cell carcinoma [ICD-11: 2C90] REF00004183 Phase 1 DG01619 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004183 Phase 1 DG01567 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004182 Phase 2 DG01567 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004182 Phase 2 DG01796 Pancreatic cancer [ICD-11: 2C10] REF00004172 Approved DG01782 Anaesthesia [ICD-11: 8E22] REF00004163 Approved DG01568 Colorectal cancer [ICD-11: 2B91] REF00004162 Phase 1 DG01773 Melasma [ICD-11: ED60] REF00004159 Approved DG01470 Head and body lice [ICD-11: 1G00] REF00004158 Approved DG01469 Psoriasis vulgaris [ICD-11: EA90] REF00004149 Approved DG01536 Myelofibrosis [ICD-11: 2A20] REF00004133 Phase 2 DG01541 Prostate cancer [ICD-11: 2C82] REF00004130 Phase 1/2 DG01541 Gastric adenocarcinoma [ICD-11: 2B72] REF00004130 Phase 1/2 DG01541 Colorectal cancer [ICD-11: 2B91] REF00004130 Phase 1/2 DG01541 Breast cancer [ICD-11: 2C60] REF00004130 Phase 1/2 DG01541 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004130 Phase 1/2 DG01541 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004130 Phase 1/2 DG01556 Triple negative breast cancer [ICD-11: 2C60-2C6Y] REF00004124 Phase 2 DG01556 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004124 Phase 2 DG01563 Clostridium infection [ICD-11: 1A04] REF00004117 Phase 2 DG01585 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004109 Phase 1/2 DG01545 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004106 Phase 2 DG01537 Breast cancer [ICD-11: 2C60] REF00004101 Approved DG01537 Breast cancer [ICD-11: 2C60] REF00004101 Approved DG01537 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004101 Approved DG01537 Non-hodgkin lymphoma [ICD-11: 2B33] REF00004101 Approved DG01511 Recurrent glioblastoma [ICD-11: 2A00] REF00004097 Phase 3 DG01511 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004097 Phase 3 DG01511 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004097 Phase 3 DG01511 Recurring respiratory infection [ICD-11: CA07-CA4Z] REF00004097 Phase 3 DG01511 Pancreatic cancer [ICD-11: 2C10] REF00004097 Phase 3 DG01511 Hepatocellular carcinoma [ICD-11: 2C12] REF00004097 Phase 3 DG01511 Haematological malignancy [ICD-11: 2B33] REF00004097 Phase 3 DG01511 Gastrointestinal cancer [ICD-11: 2B5B] REF00004097 Phase 3 DG01511 Colorectal cancer [ICD-11: 2B91] REF00004097 Phase 3 DG01511 Advanced malignancy [ICD-11: 2A00-2F9Z] REF00004097 Phase 3 DG01511 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004097 Phase 3 DG01596 Discovery agent [ICD-11: N.A.] REF00004092 Phase 2 DG01497 Lupus nephritis [ICD-11: 4A40] REF00004079 Phase 3 DG01497 Psoriasis vulgaris [ICD-11: EA90] REF00004079 Phase 3 DG01497 Kidney disease [ICD-11: GC2Z] REF00004079 Phase 3 DG01772 Infectious disease [ICD-11: 1A00-CA43] REF00004075 Approved DG01802 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00004070 Phase 2 DG01577 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004069 Phase 2 DG01577 Multiple myeloma [ICD-11: 2A83] REF00004069 Phase 2 DG01577 leukaemia [ICD-11: 2A60-2B33] REF00004069 Phase 2 DG01506 Thyroid cancer [ICD-11: 2D10] REF00004055 Phase 2 DG01506 Melanoma [ICD-11: 2C30] REF00004055 Phase 2 DG01506 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004055 Phase 2 DG01506 Non-small-cell lung cancer [ICD-11: 2C25] REF00004055 Phase 2 DG01474 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004036 Phase 1 DG01474 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004036 Phase 1 DG01474 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004036 Phase 1 DG01495 Multiple myeloma [ICD-11: 2A83] REF00004032 Terminated DG01495 Breast cancer [ICD-11: 2C60] REF00004032 Terminated DG01520 Non-small-cell lung cancer [ICD-11: 2C25] REF00004022 Phase 2 DG01785 Breast cancer [ICD-11: 2C60] REF00004019 Approved DG01816 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004017 Preclinical DG01641 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004000 Phase 3 DG01612 Discovery agent [ICD-11: N.A.] REF00003999 Phase 2 DG01591 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003997 Phase 3 DG01540 Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00] REF00003996 Phase 3 DG01540 Basal cell carcinoma [ICD-11: 2C32] REF00003996 Phase 3 DG01543 Discovery agent [ICD-11: N.A.] REF00003978 Approved DG01510 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00003967 Phase 3 DG01522 Non-small-cell lung cancer [ICD-11: 2C25] REF00003966 Investigative DG01505 Parkinson disease [ICD-11: 8A00] REF00003962 Phase 3 DG01505 Parkinson disease [ICD-11: 8A00] REF00003962 Phase 3 DG01538 Prostate cancer [ICD-11: 2C82] REF00003960 Phase 1 DG01538 Pancreatic cancer [ICD-11: 2C10] REF00003960 Phase 1 DG01538 Ovarian cancer [ICD-11: 2C73] REF00003960 Phase 1 DG01538 Ovarian cancer [ICD-11: 2C73] REF00003960 Phase 1 DG01466 Heart block [ICD-11: BC63] REF00003942 Investigative DG01466 Melanoma [ICD-11: 2C30] REF00003942 Investigative DG01465 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003941 Investigative DG01475 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003940 Approved DG01788 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003934 Approved DG01643 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00003933 Phase 1/2 DG01549 Thrombocythemia [ICD-11: 3B63] REF00003930 Investigative DG01549 Polycythemia vera [ICD-11: 2A20] REF00003930 Investigative DG01668 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003930 Phase 2 DG01548 Endometrial cancer [ICD-11: 2C76] REF00003930 Phase 3 DG01549 Myelofibrosis [ICD-11: 2A20] REF00003930 Investigative DG01638 Discovery agent [ICD-11: N.A.] REF00003918 Phase 3 DG01578 Chronic myelogenous leukaemia [ICD-11: 2A20] REF00003916 Phase 1/2 DG01800 Hypercholesterolaemia [ICD-11: 5C80] REF00003906 Approved DG01534 Myeloproliferative syndrome [ICD-11: 2A20] REF00003902 Discontinued in Phase 1 DG01822 Obesity [ICD-11: 5B81] REF00003899 Approved DG01786 Discovery agent [ICD-11: N.A.] REF00003899 Investigative DG01847 Diabetic complication [ICD-11: 5A2Y] REF00003899 Approved DG01464 Colorectal cancer [ICD-11: 2B91] REF00003898 Approved DG01464 Tumour [ICD-11: 2A00-2F9Z] REF00003898 Approved DG01464 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003898 Approved DG01464 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003898 Approved DG01840 Caerulein stimulated gastric and pancreatic secretion [ICD-11: 5A4Y] REF00003897 Approved DG01840 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003897 Approved DG01824 Discovery agent [ICD-11: N.A.] REF00003895 Investigative DG01472 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003880 Investigative DG01787 Influenza virus infection [ICD-11: 1E30-1E32] REF00003877 Investigative DG01805 Discovery agent [ICD-11: N.A.] REF00003877 Investigative DG01642 Acute myelogenous leukaemia [ICD-11: 2A60] REF00003872 Phase 1 DG01642 Acute myeloid leukaemia [ICD-11: 2A60] REF00003872 Phase 1 DG01789 Piscicide [ICD-11: N.A.] REF00003868 Approved DG01087 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003864 Approved DG01037 Skin disease [ICD-11: EA00-EM0Z] REF00003863 Approved DG01053 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003862 Approved DG00801 Psychomotor agitation [ICD-11: MB23] REF00003861 Approved DG01186 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003860 Approved DG01161 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003859 Approved DG00739 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003858 Approved DG00951 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003857 Approved DG00963 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003856 Approved DG01157 Hypertension [ICD-11: BA00] REF00003855 Approved DG01010 Kidney disease [ICD-11: GC2Z] REF00003854 Approved DG01010 Hyperparathyroidism [ICD-11: 5A51] REF00003854 Approved DG01397 Pain [ICD-11: MG30] REF00003853 Approved DG00667 MRSA infection [ICD-11: 1D01] REF00003850 Approved DG00667 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003850 Approved DG00789 Hypercalcaemia [ICD-11: 5B91] REF00003848 Approved DG01181 Lupus nephritis [ICD-11: 4A40] REF00003826 Approved DG01181 Psoriasis vulgaris [ICD-11: EA90] REF00003826 Approved DG01181 Kidney disease [ICD-11: GC2Z] REF00003826 Approved DG00646 Worm infection [ICD-11: 1F90] REF00003824 Approved DG00628 Breast cancer [ICD-11: 2C60] REF00003823 Investigative DG00628 Multiple myeloma [ICD-11: 2A83] REF00003823 Investigative DG00628 Multiple myeloma [ICD-11: 2A83] REF00003823 Investigative DG01126 Diabetic complication [ICD-11: 5A2Y] REF00003820 Approved DG01117 Open-angle glaucoma [ICD-11: 9C61] REF00003819 Approved DG01254 Non-small-cell lung cancer [ICD-11: 2C25] REF00003816 Approved DG01226 Psoriasis vulgaris [ICD-11: EA90] REF00003815 Approved DG01234 Prostate cancer [ICD-11: 2C82] REF00003811 Approved DG01062 Prostate cancer [ICD-11: 2C82] REF00003811 Approved DG00672 Age-related macular degeneration [ICD-11: 9B75] REF00003809 Approved DG01348 Asthma [ICD-11: CA23] REF00003808 Approved DG01333 Heart transplant rejection [ICD-11: NE84] REF00003805 Approved DG01333 Kidney transplant rejection [ICD-11: NE84] REF00003805 Approved DG00855 Migraine [ICD-11: 8A80] REF00003804 Approved DG00855 Obesity [ICD-11: 5B81] REF00003804 Approved DG01412 Respiratory syncytial virus infection [ICD-11: 1C80] REF00003803 Approved DG00946 Depression [ICD-11: 6A70] REF00003802 Approved DG00890 Hereditary angioedema [ICD-11: 4A00] REF00003801 Approved DG01408 Rheumatoid arthritis [ICD-11: FA20] REF00003800 Approved DG00976 Fungal infection [ICD-11: 1F29-1F2F] REF00003798 Approved DG01155 Malaria [ICD-11: 1F45] REF00003798 Approved DG01033 Skin allergy [ICD-11: 4A80-4A8Z] REF00003797 Approved DG00651 Colorectal cancer [ICD-11: 2B91] REF00003792 Approved DG00651 Lung cancer [ICD-11: 2C25] REF00003792 Approved DG00651 Brain metastases [ICD-11: 2D50-2E2Z] REF00003792 Approved DG00651 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003792 Approved DG00651 Ovarian cancer [ICD-11: 2C73] REF00003792 Approved DG00651 Metastatic colorectal cancer [ICD-11: 2D85] REF00003792 Approved DG00651 Metastatic colorectal cancer [ICD-11: 2D85] REF00003792 Approved DG00674 Impetigo [ICD-11: 1B72] REF00003790 Approved DG01189 Type-2 diabetes [ICD-11: 5A11] REF00003787 Approved DG00994 Parkinson disease [ICD-11: 8A00] REF00003784 Approved DG00800 Nausea [ICD-11: MD90] REF00003779 Approved DG00795 Schizophrenia [ICD-11: 6A20] REF00003779 Approved DG01431 Hodgkin lymphoma [ICD-11: 2B30] REF00003778 Approved DG01152 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003775 Approved DG01377 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003767; REF00003825 Approved DG00802 Allergy [ICD-11: 4A85] REF00003762 Approved DG01274 Migraine [ICD-11: 8A80] REF00003758 Approved DG01217 Migraine [ICD-11: 8A80] REF00003758 Approved DG01369 Hyperprolactinaemia [ICD-11: 5A60-5A61] REF00003758 Approved DG01376 Hyperprolactinaemia [ICD-11: 5A60-5A61] REF00003758 Approved DG01378 Hyperprolactinaemia [ICD-11: 5A60-5A61] REF00003758 Approved DG00929 Cutaneous T-cell lymphoma [ICD-11: 2B00] REF00003757 Investigative DG00929 Actinic keratosis [ICD-11: EK90] REF00003757 Investigative DG00929 Herpes simplex virus infection [ICD-11: 1F00] REF00003757 Investigative DG00928 Skin cancer [ICD-11: 2C30-2C37] REF00003757 Investigative DG00999 Allergic rhinitis [ICD-11: CA08] REF00003756 Approved DG01007 Euvolemic hyponatremia [ICD-11: 5C72] REF00003756 Approved DG01066 Depression [ICD-11: 6A70] REF00003755 Approved DG00863 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003753 Approved DG01160 Nausea [ICD-11: MD90] REF00003748 Approved DG00593 Muscle spasm [ICD-11: MB47] REF00003744 Approved DG00952 Open-angle glaucoma [ICD-11: 9C61] REF00003743 Approved DG01076 Metal intoxication [ICD-11: NE60] REF00003742 Approved DG00842 Discovery agent [ICD-11: N.A.] REF00003742 Approved DG01101 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003741 Investigative DG01223 Complex partial seizure [ICD-11: 8A61-8A6Z] REF00003740 Approved DG01149 Osteoporosis [ICD-11: FB83] REF00003739 Approved DG00985 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003738 Approved DG00748 Castleman's disease [ICD-11: 4B2Y] REF00003737 Approved DG00748 Amyotrophic lateral sclerosis [ICD-11: 8B60] REF00003737 Approved DG00748 Opioid dependence [ICD-11: 6C43] REF00003737 Approved DG00748 Methamphetamine dependence [ICD-11: 6C46] REF00003737 Approved DG00748 Alcohol dependence [ICD-11: 6C40] REF00003737 Approved DG00748 Multiple sclerosis [ICD-11: 8A40] REF00003737 Approved DG01015 Duchenne dystrophy [ICD-11: 8C70] REF00003735 Approved DG00752 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003734 Approved DG01191 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003728 Approved DG01191 Breast cancer [ICD-11: 2C60] REF00003728 Approved DG00981 Prostate cancer [ICD-11: 2C82] REF00003724 Approved DG00981 Prostate cancer [ICD-11: 2C82] REF00003724 Approved DG01418 Hyperuricaemia [ICD-11: 5C55] REF00003720 Approved DG00626 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003718 Investigative DG00627 Discovery agent [ICD-11: N.A.] REF00003718 Investigative DG00575 Perianal crohn disease [ICD-11: DD70] REF00003716 Approved DG00575 Amoebiasis [ICD-11: 1A36] REF00003716 Approved DG00575 Crohn disease [ICD-11: DD70] REF00003716 Approved DG00805 Osteoporosis [ICD-11: FB83] REF00003715 Approved DG00805 Osteoporosis [ICD-11: FB83] REF00003715 Approved DG01314 Essential thrombocythemia [ICD-11: 3B63] REF00003714 Approved DG01314 Thrombocythemia [ICD-11: 3B63] REF00003714 Approved DG00850 Contraception [ICD-11: QA21] REF00003714 Approved DG00984 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003714 Approved DG00923 Asthma [ICD-11: CA23] REF00003713 Approved DG01145 Multi-drug resistant tuberculosis [ICD-11: MG50-MG52] REF00003711 Approved DG00693 Throat irritation [ICD-11: CA0Z] REF00003709 Approved DG00844 Hypertension [ICD-11: BA00] REF00003706 Approved DG00724 Functional bowel syndrome [ICD-11: DD91] REF00003704 Approved DG01003 Hyperuricaemia [ICD-11: 5C55] REF00003703 Approved DG00620 Essential thrombocythemia [ICD-11: 3B63] REF00003699 Approved DG00620 Essential thrombocythemia [ICD-11: 3B63] REF00003699 Approved DG00620 Vitiligo [ICD-11: ED63] REF00003699 Approved DG00620 Atopic dermatitis [ICD-11: EA80] REF00003699 Approved DG00620 Pancreatic cancer [ICD-11: 2C10] REF00003699 Approved DG00620 High-risk myelofibrosis [ICD-11: 2A20] REF00003699 Approved DG01406 Triple negative breast cancer [ICD-11: 2C60-2C6Y] REF00003698 Approved DG01406 Small-cell lung cancer [ICD-11: 2C25] REF00003698 Approved DG01406 Renal cell carcinoma [ICD-11: 2C90] REF00003698 Approved DG01406 Recurrent glioblastoma [ICD-11: 2A00] REF00003698 Approved DG01406 Prostate cancer [ICD-11: 2C82] REF00003698 Approved DG01406 Pancreatic cancer [ICD-11: 2C10] REF00003698 Approved DG01406 Ovarian cancer [ICD-11: 2C73] REF00003698 Approved DG01406 Multiple myeloma [ICD-11: 2A83] REF00003698 Approved DG01406 Malignant pleural mesothelioma [ICD-11: 2C26] REF00003698 Approved DG01406 Gastric adenocarcinoma [ICD-11: 2B72] REF00003698 Approved DG01406 Gastric adenocarcinoma [ICD-11: 2B72] REF00003698 Approved DG01406 Follicular lymphoma [ICD-11: 2A80] REF00003698 Approved DG01406 Esophageal cancer [ICD-11: 2B70] REF00003698 Approved DG01406 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00003698 Approved DG01406 Chronic myelogenous leukaemia [ICD-11: 2A20] REF00003698 Approved DG01406 Central nervous system lymphoma [ICD-11: 2B33] REF00003698 Approved DG01406 Non-small-cell lung cancer [ICD-11: 2C25] REF00003698 Approved DG01406 Melanoma [ICD-11: 2C30] REF00003698 Approved DG01243 Breast cancer [ICD-11: 2C60] REF00003695 Approved DG00924 Cushing disease [ICD-11: 5A70] REF00003693 Approved DG01405 Head and neck cancer [ICD-11: 2D42] REF00003692 Approved DG00898 Respiratory distress syndrome [ICD-11: CB00] REF00003689 Approved DG01154 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003686 Approved DG01011 Liver disease [ICD-11: DB90-DB9Z] REF00003683 Approved DG01166 Renal cell carcinoma [ICD-11: 2C90] REF00003682 Approved DG01256 Prostate cancer [ICD-11: 2C82] REF00003681 Registered DG00571 Primary Immunodeficiency [ICD-11: 4A01] REF00003680 Approved DG00922 Hyperprolactinaemia [ICD-11: 5A60-5A61] REF00003679 Approved DG01104 Peptic ulcer [ICD-11: DA61] REF00003678 Approved DG01370 Menopause symptom [ICD-11: GA30] REF00003677 Approved DG00843 Nephropathic cystinosis [ICD-11: 5C60] REF00003676 Approved DG01242 Inflammatory arthritis [ICD-11: FA2Z] REF00003674 Approved DG00725 Lymphatic filariasis [ICD-11: 1F66] REF00003673 Approved DG00653 Worm infection [ICD-11: 1F90] REF00003673 Approved DG00650 Hereditary hemorrhagic telangiectasia [ICD-11: LA90] REF00003672 Approved DG01321 Angina pectoris [ICD-11: BA40] REF00003671 Approved DG00546 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003670 Investigative DG00546 Ovarian cancer [ICD-11: 2C73] REF00003670 Investigative DG01068 Pruritus [ICD-11: EC90] REF00003668 Approved DG01450 Meningitis [ICD-11: 1D01] REF00003667 Approved DG01180 Acute coronary syndrome [ICD-11: BA41-BA43] REF00003665 Approved DG01112 Psoriasis vulgaris [ICD-11: EA90] REF00003663 Approved DG01241 Arthropathy [ICD-11: FA11-FA5Z] REF00003660 Approved DG00624 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003659 Investigative DG01429 Bone marrow transplantation [ICD-11: QB63] REF00003658 Approved DG01067 Anaesthesia [ICD-11: 8E22] REF00003656 Approved DG00727 Meniere disease [ICD-11: AB31] REF00003655 Approved DG00761 Pain [ICD-11: MG30] REF00003652 Approved DG00761 Osteoarthritis [ICD-11: FA00-FA05] REF00003652 Approved DG00761 Migraine [ICD-11: 8A80] REF00003652 Approved DG00761 Musculoskeletal pain [ICD-11: MG30] REF00003652 Approved DG00761 Pain [ICD-11: MG30] REF00003652 Approved DG01301 Tourette syndrome [ICD-11: 8A05] REF00003651 Approved DG01301 Tardive dyskinesia [ICD-11: 8A02] REF00003651 Approved DG01299 Tardive dyskinesia [ICD-11: 8A02] REF00003651 Approved DG01299 Huntington disease [ICD-11: 8A01] REF00003651 Approved DG01300 Hyperkinetic movement disorder [ICD-11: 6B60] REF00003651 Approved DG01300 Huntington disease [ICD-11: 8A01] REF00003651 Approved DG00988 Alcohol dependence [ICD-11: 6C40] REF00003649 Approved DG01173 Hyperthermia [ICD-11: MG26] REF00003646 Approved DG00868 Attention deficit hyperactivity disorder [ICD-11: 6A05] REF00003643 Approved DG00868 Pain [ICD-11: MG30] REF00003643 Approved DG01153 High blood pressure [ICD-11: BA00] REF00003642 Approved DG00695 Alzheimer disease [ICD-11: 8A20] REF00003641 Approved DG00888 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003637 Approved DG01102 Bronchitis [ICD-11: CA20] REF00003636 Approved DG01143 Pain [ICD-11: MG30] REF00003632 Approved DG01119 Insomnia [ICD-11: 7A00] REF00003631 Approved DG01092 Parkinson disease [ICD-11: 8A00] REF00003631 Approved DG00762 Postoperative inflammation [ICD-11: 1A00-CA43] REF00003630 Approved DG01213 Chronic obstructive pulmonary disease [ICD-11: CA22] REF00003628 Approved DG01291 Small-cell lung cancer [ICD-11: 2C25] REF00003627 Approved DG01291 Triple negative breast cancer [ICD-11: 2C60-2C6Y] REF00003627 Approved DG01232 Pediatric growth disorder [ICD-11: FB86] REF00003622 Approved DG00587 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003611 Approved DG00956 Malaria [ICD-11: 1F45] REF00003609 Approved DG00956 Malaria [ICD-11: 1F45] REF00003609 Approved DG00931 Acute supraventricular tachycardia [ICD-11: BC81] REF00003603 Approved DG00788 Schistosomiasis [ICD-11: 1F86] REF00003598 Approved DG00637 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00637 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00641 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00641 Seizure disorder [ICD-11: 8A61-8A6Z] REF00003593 Approved DG00637 Type-1 diabetes [ICD-11: 5A10] REF00003593 Approved DG00638 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00641 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00641 Alcohol dependence [ICD-11: 6C40] REF00003593 Approved DG00640 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00595 Seizure disorder [ICD-11: 8A61-8A6Z] REF00003593 Approved DG00639 Epilepsy [ICD-11: 8A60] REF00003593 Approved DG00639 Bipolar disorder [ICD-11: 6A60] REF00003593 Approved DG00638 Alcohol dependence [ICD-11: 6C40] REF00003593 Approved DG00640 Fibromyalgia [ICD-11: MG30] REF00003593 Approved DG00637 Gastric adenocarcinoma [ICD-11: 2B72] REF00003593 Approved DG00659 Erectile dysfunction [ICD-11: HA00-HA01] REF00003590 Approved DG00661 Visceral leishmaniasis [ICD-11: 1F54] REF00003589 Approved DG00661 Leishmaniasis [ICD-11: 1F54] REF00003589 Approved DG01022 Parasitic infection [ICD-11: 1D0Y-1G2Z] REF00003581 Approved DG01121 Pain [ICD-11: MG30] REF00003578 Approved DG01121 Pain [ICD-11: MG30] REF00003578 Approved DG01121 Back pain [ICD-11: ME84] REF00003578 Approved DG01014 Breast cancer [ICD-11: 2C60] REF00003573 Approved DG01236 HIV-associated lipodystrophy [ICD-11: 1C60-1C62] REF00003567 Approved DG01263 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003564 Approved DG01263 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003564 Approved DG01263 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003564 Approved DG00648 Chronic lymphocytic leukaemia [ICD-11: 2A82] REF00003563 Approved DG00648 Chronic lymphocytic leukaemia [ICD-11: 2A82] REF00003563 Approved DG01388 Melanoma [ICD-11: 2C30] REF00003560 Approved DG00880 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003559 Approved DG00764 Major depressive disorder [ICD-11: 6A70-6A7Z] REF00003557 Approved DG01255 Overactive bladder [ICD-11: GC50] REF00003554 Approved DG00735 Glaucoma/ocular hypertension [ICD-11: 9C61] REF00003553 Approved DG00735 Duodenal ulcer [ICD-11: DA63] REF00003553 Approved DG00901 Chagas disease [ICD-11: 1F53] REF00003551 Approved DG00901 Trypanosomiasis [ICD-11: 1D51-1F53] REF00003551 Approved DG01021 Virus infection [ICD-11: 1A24-1D9Z] REF00003550 Approved DG01021 Osteoporosis [ICD-11: FB83] REF00003550 Approved DG01107 Ocular allergy [ICD-11: 4A80-4A8Z] REF00003547 Approved DG01375 Deep vein thrombosis [ICD-11: BD71] REF00003544 Approved DG01375 Pulmonary embolism [ICD-11: BB00] REF00003544 Approved DG01375 Deep vein thrombosis [ICD-11: BD71] REF00003544 Approved DG01069 Worm infection [ICD-11: 1F90] REF00003541 Approved DG00867 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003539 Approved DG01046 Gonorrheal vaginitis [ICD-11: GA02] REF00003538 Approved DG00553 Tenosynovial giant cell tumour [ICD-11: 2F7B] REF00003537 Approved DG00553 Tenosynovial giant cell tumour [ICD-11: 2F7B] REF00003537 Approved DG00553 Pigmented villonodular synovitis [ICD-11: FA2Z] REF00003537 Approved DG00553 Neurofibromatosis type 1 [ICD-11: LD2D] REF00003537 Approved DG00553 Alzheimer disease [ICD-11: 8A20] REF00003537 Approved DG01096 Worm infection [ICD-11: 1F90] REF00003533 Approved DG01041 Hypercholesterolaemia [ICD-11: 5C80] REF00003530 Approved DG01270 Non-hodgkin lymphoma [ICD-11: 2B33] REF00003529 Approved DG01270 Non-hodgkin lymphoma [ICD-11: 2B33] REF00003529 Approved DG01271 Small lymphocytic lymphoma [ICD-11: 2A82] REF00003529 Approved DG01271 Follicular lymphoma [ICD-11: 2A80] REF00003529 Approved DG01270 Follicular lymphoma [ICD-11: 2A80] REF00003529 Approved DG01271 Arthritis [ICD-11: FA20] REF00003529 Approved DG01002 Virus infection [ICD-11: 1A24-1D9Z] REF00003525 Approved DG01020 Respiratory tract infection [ICD-11: CA07-CA4Z] REF00003520 Approved DG01195 Pulmonary arterial hypertension [ICD-11: BB01] REF00003518 Approved DG00652 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003515 Investigative DG00652 Multiple myeloma [ICD-11: 2A83] REF00003515 Investigative DG00652 leukaemia [ICD-11: 2A60-2B33] REF00003515 Investigative DG01401 T-cell leukaemia [ICD-11: 2A90] REF00003514 Approved DG01401 Cutaneous T-cell lymphoma [ICD-11: 2B00] REF00003514 Approved DG01401 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003514 Approved DG01401 Sezary syndrome [ICD-11: 2B02] REF00003514 Approved DG01401 Sezary syndrome [ICD-11: 2B02] REF00003514 Approved DG01401 Mycosis fungoides [ICD-11: 2B01] REF00003514 Approved DG01401 Mycosis fungoides [ICD-11: 2B01] REF00003514 Approved DG01268 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003512 Approved DG01268 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003512 Approved DG01268 Chronic lymphocytic leukaemia [ICD-11: 2A82] REF00003512 Approved DG01004 Systemic sclerosis [ICD-11: 4A42] REF00003511 Approved DG01105 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003510 Approved DG01310 Virus infection [ICD-11: 1A24-1D9Z] REF00003509 Approved DG00549 Thrombosis [ICD-11: DB61-GB90] REF00003504 Approved DG00548 Pain [ICD-11: MG30] REF00003504 Approved DG00548 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00003504 Approved DG00548 Myocardial infarction [ICD-11: BA41] REF00003504 Approved DG01060 Pseudomonas infection [ICD-11: 1B92] REF00003503 Approved DG00876 Head and body lice [ICD-11: 1G00] REF00003501 Approved DG00982 Thrombosis [ICD-11: DB61-GB90] REF00003500 Approved DG00654 Hyperthyroidism [ICD-11: 5A02] REF00003497 Approved DG00977 Sjogren syndrome [ICD-11: 4A43] REF00003496 Approved DG01451 Mycobacterium infection [ICD-11: 1B10-1B21] REF00003493 Approved DG01436 Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60] REF00003491 Approved DG01436 Acute myeloid leukaemia [ICD-11: 2A60] REF00003491 Approved DG00656 Idiopathic pulmonary fibrosis [ICD-11: CB03] REF00003490 Approved DG01245 Diabetic nephropathy [ICD-11: GB61] REF00003486 Approved DG01245 Type-1 diabetes [ICD-11: 5A10] REF00003486 Approved DG01245 Type-2 diabetes [ICD-11: 5A11] REF00003486 Approved DG01245 Type-2 diabetes [ICD-11: 5A11] REF00003486 Approved DG01158 Hypertension [ICD-11: BA00] REF00003482 Approved DG00920 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00003477 Approved DG00920 Hypercholesterolaemia [ICD-11: 5C80] REF00003477 Approved DG01165 Osteoarthritis [ICD-11: FA00-FA05] REF00003476 Approved DG00961 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003475 Approved DG00908 Acute lymphoblastic leukaemia [ICD-11: 2A70] REF00003474 Approved DG00892 Hypertension [ICD-11: BA00] REF00003473 Approved DG01363 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003472 Approved DG01363 Pancreatic ductal carcinoma [ICD-11: 2C10] REF00003472 Approved DG01363 Melanoma [ICD-11: 2C30] REF00003472 Approved DG01363 Hepatocellular carcinoma [ICD-11: 2C12] REF00003472 Approved DG01363 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00003472 Approved DG01363 Biliary tract cancer [ICD-11: 2C15] REF00003472 Approved DG01363 Ureteral cancer [ICD-11: 2C92] REF00003472 Approved DG01304 Cholangiocarcinoma [ICD-11: 2C12] REF00003471 Approved DG01304 Myeloproliferative syndrome [ICD-11: 2A20] REF00003471 Approved DG01304 Bladder cancer [ICD-11: 2C94] REF00003471 Approved DG01306 Gastrointestinal stromal tumour [ICD-11: 2B5B] REF00003470 Approved DG01306 Systemic mastocytosis [ICD-11: 2A21] REF00003470 Approved DG01306 Mast cell leukaemia [ICD-11: 2A21] REF00003470 Approved DG00581 Cholangiocarcinoma [ICD-11: 2C12] REF00003469 Investigative DG00581 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003469 Investigative DG00581 Multiple myeloma [ICD-11: 2A83] REF00003469 Investigative DG01182 Multiple myeloma [ICD-11: 2A83] REF00003466 Approved DG01182 Primary myelofibrosis [ICD-11: 2A20] REF00003466 Approved DG01182 Type-2 diabetes [ICD-11: 5A11] REF00003466 Approved DG00630 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003465 Phase 2 DG00632 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00003465 Investigative DG00677 Melanoma [ICD-11: 2C30] REF00003464 Approved DG00642 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003462 Investigative DG00642 Melanoma [ICD-11: 2C30] REF00003462 Investigative DG01315 Irritable bowel syndrome [ICD-11: DD91] REF00003459 Approved DG01315 Irritable bowel syndrome [ICD-11: DD91] REF00003459 Approved DG01315 Gastro-oesophageal reflux [ICD-11: DA22] REF00003459 Approved DG01315 Dyspepsia [ICD-11: MD92] REF00003459 Approved DG00791 Spasm [ICD-11: MB47] REF00003458 Approved DG00754 X-rays imaging [ICD-11: N.A.] REF00003457 Approved DG01148 Skin burns [ICD-11: ME65] REF00003449 Approved DG01148 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003449 Approved DG00897 Hyperthyroidism [ICD-11: 5A02] REF00003447 Approved DG01193 Melanoma [ICD-11: 2C30] REF00003446 Approved DG01305 Crohn disease [ICD-11: DD70] REF00003445 Approved DG00915 Angina pectoris [ICD-11: BA40] REF00003444 Approved DG01216 Urinary tract infection [ICD-11: GC08] REF00003442 Approved DG00998 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003441 Approved DG00839 Glioma [ICD-11: 2A00] REF00003440 Approved DG00839 Dietary shortage [ICD-11: 5B5K] REF00003440 Approved DG00856 Sepsis [ICD-11: 1G40] REF00003439 Approved DG01176 Obstructive airway disease [ICD-11: CB40-CB7Z] REF00003438 Approved DG01176 Asthma [ICD-11: CA23] REF00003438 Approved DG00644 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] REF00003436 Investigative DG00644 Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] REF00003436 Investigative DG00644 Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] REF00003436 Investigative DG00608 Influenza virus infection [ICD-11: 1E30-1E32] REF00003434 Approved DG01140 Narcotic depression [ICD-11: 6A70-6A7Z] REF00003433 Approved DG01419 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003432 Approved DG00989 Primary progressive multiple sclerosis [ICD-11: 8A40] REF00003431 Approved DG00983 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003430 Approved DG00882 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003429 Approved DG00914 Candidiasis [ICD-11: 1F23] REF00003426 Approved DG00941 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003425 Approved DG00975 Chronic bronchitis [ICD-11: CA20] REF00003424 Approved DG00975 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003424 Approved DG00919 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003422; REF00003531 Approved DG01168 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003421 Approved DG00945 Urinary tract infection [ICD-11: GC08] REF00003420 Approved DG01025 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003419 Approved DG01171 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003418 Approved DG01051 Microorganisms infection [ICD-11: 1A00-1A09] REF00003417 Approved DG01162 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003416 Approved DG00904 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003415 Approved DG01008 Influenza virus infection [ICD-11: 1E30-1E32] REF00003414 Approved DG01286 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003413 Approved DG01286 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003413 Approved DG00939 Hepatitis B virus infection [ICD-11: 1E50-1E51] REF00003412 Approved DG00939 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003412 Approved DG00939 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00003412 Approved DG01184 Mycobacterium infection [ICD-11: 1B10-1B21] REF00003411 Approved DG01212 Onychomycosis [ICD-11: EE12] REF00003410 Approved DG00666 Discovery agent [ICD-11: N.A.] REF00003409 Approved DG00916 Dermatomycosis [ICD-11: EA60] REF00003407 Approved DG01170 Multi-drug resistant tuberculosis [ICD-11: MG50-MG52] REF00003405 Approved DG01170 Mycobacterium infection [ICD-11: 1B10-1B21] REF00003405 Approved DG01156 Diarrhea [ICD-11: DA90] REF00003404 Approved DG01156 Infectious disease [ICD-11: 1A00-CA43] REF00003404 Approved DG01074 Pain [ICD-11: MG30] REF00003401 Approved DG01074 Diabetic neuropathy [ICD-11: 8C0Z] REF00003401 Approved DG00596 Epilepsy [ICD-11: 8A60] REF00003399 Approved DG00623 Epilepsy [ICD-11: 8A60] REF00003399 Approved DG01114 Pain [ICD-11: MG30] REF00003396 Approved DG01114 Cough [ICD-11: MD12] REF00003396 Approved DG01081 Dry eye disease [ICD-11: 9E1Z] REF00003395 Approved DG01081 Tinea pedis [ICD-11: 1F28] REF00003395 Approved DG01081 Tinea pedis [ICD-11: 1F28] REF00003395 Approved DG00660 Medulloblastoma [ICD-11: 2A00] REF00003390 Approved DG00660 Skin cancer [ICD-11: 2C30-2C37] REF00003390 Approved DG00707 Glaucoma/ocular hypertension [ICD-11: 9C61] REF00003389 Approved DG00707 Ocular hypertension [ICD-11: 9C61] REF00003389 Approved DG00823 Nausea [ICD-11: MD90] REF00003388 Approved DG01385 Reversal of the anticoagulant effects of dabigatran [ICD-11:N.A.] REF00003383 Approved DG01214 Non-small-cell lung cancer [ICD-11: 2C25] REF00003379 Approved DG01214 Non-small-cell lung cancer [ICD-11: 2C25] REF00003379 Approved DG01214 Non-small-cell lung cancer [ICD-11: 2C25] REF00003379 Approved DG00545 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003377 Investigative DG00617 Thyroid cancer [ICD-11: 2D10] REF00003376 Approved DG00617 Thyroid cancer [ICD-11: 2D10] REF00003376 Approved DG00617 Ovarian cancer [ICD-11: 2C73] REF00003376 Approved DG00619 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003376 Approved DG01443 Plaque psoriasis [ICD-11: EA90] REF00003369 Approved DG01044 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003366 Approved DG01082 Pain [ICD-11: MG30] REF00003362 Approved DG01262 Type-2 diabetes [ICD-11: 5A11] REF00003361 Approved DG01262 Type-2 diabetes [ICD-11: 5A11] REF00003361 Approved DG01262 Type-2 diabetes [ICD-11: 5A11] REF00003361 Approved DG01262 Type-2 diabetes [ICD-11: 5A11] REF00003361 Approved DG01262 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00003361 Approved DG00937 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00003360 Approved DG00662 Herpes simplex virus infection [ICD-11: 1F00] REF00003354 Approved DG00662 Virus infection [ICD-11: 1A24-1D9Z] REF00003354 Approved DG01038 Ischemic stroke [ICD-11: 8B11] REF00003350 Approved DG00933 Spasm [ICD-11: MB47] REF00003348 Approved DG01423 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003342 Approved DG01027 Osteoarthritis [ICD-11: FA00-FA05] REF00003340 Approved DG00569 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00003337 Approved DG00847 Obsessive compulsive disorder [ICD-11: 6B20] REF00003336 Approved DG00847 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003336 Approved DG00847 Tuberculosis [ICD-11: 1B10] REF00003336 Approved DG01417 Bleeding disorder [ICD-11: GA20-GA21] REF00003335 Approved DG01206 Skin infection [ICD-11: 1F28-1G0Z] REF00003334 Approved DG01308 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003332 Approved DG01050 Tuberculosis [ICD-11: 1B10] REF00003331 Approved DG01050 Mycobacterium infection [ICD-11: 1B10-1B21] REF00003331 Approved DG00681 Mycobacterium infection [ICD-11: 1B10-1B21] REF00003326 Approved DG00938 Hypertension [ICD-11: BA00] REF00003325 Approved DG01295 Heart failure [ICD-11: BD10] REF00003325 Approved DG00645 Malaria [ICD-11: 1F45] REF00003321 Approved DG00645 Malaria [ICD-11: 1F45] REF00003321 Approved DG00809 Spasm [ICD-11: MB47] REF00003320 Approved DG00966 Bacterial vaginosis [ICD-11: MF3A] REF00003315 Approved DG00966 Amoebiasis [ICD-11: 1A36] REF00003315 Approved DG00583 Glaucoma/ocular hypertension [ICD-11: 9C61] REF00003314 Approved DG00583 Glaucoma/ocular hypertension [ICD-11: 9C61] REF00003314 Approved DG00583 Ocular disease [ICD-11: 1F00] REF00003314 Approved DG00583 Open-angle glaucoma [ICD-11: 9C61] REF00003314 Approved DG00582 Alopecia [ICD-11: ED70] REF00003314 Approved DG00582 Glaucoma/ocular hypertension [ICD-11: 9C61] REF00003314 Approved DG00552 Rheumatoid arthritis [ICD-11: FA20] REF00003313 Approved DG00588 Cytomegalovirus retinitis [ICD-11: 9B72] REF00003310 Approved DG00589 Cytomegalovirus infection [ICD-11: 1D82] REF00003310 Approved DG01201 Parkinson disease [ICD-11: 8A00] REF00003307 Approved DG01201 Parkinson disease [ICD-11: 8A00] REF00003307 Approved DG00860 Myelodysplastic syndrome [ICD-11: 2A37] REF00003303 Approved DG00860 Myelodysplastic syndrome [ICD-11: 2A37] REF00003303 Approved DG01350 Plaque psoriasis [ICD-11: EA90] REF00003300 Approved DG01350 Plaque psoriasis [ICD-11: EA90] REF00003300 Approved DG01350 Asthma [ICD-11: CA23] REF00003300 Approved DG01322 Rheumatoid arthritis [ICD-11: FA20] REF00003300 Approved DG00678 Pulmonary tuberculosis [ICD-11: 1B10-1B12] REF00003293 Approved DG00883 Multiple sclerosis [ICD-11: 8A40] REF00003290 Approved DG00883 Relapsing-remitting multiple sclerosis [ICD-11: 8A40] REF00003290 Approved DG00883 Hairy cell leukaemia [ICD-11: 2A82] REF00003290 Approved DG01054 Fungal infection [ICD-11: 1F29-1F2F] REF00003288 Approved DG01460 Multiple myeloma [ICD-11: 2A83] REF00003282 Approved DG01172 Chagas disease [ICD-11: 1F53] REF00003281 Approved DG01172 Trypanosomiasis [ICD-11: 1D51-1F53] REF00003281 Approved DG01366 Ureteral cancer [ICD-11: 2C92] REF00003279 Approved DG01366 Ureteral cancer [ICD-11: 2C92] REF00003279 Approved DG00829 Hypertension [ICD-11: BA00] REF00003271 Approved DG00829 Edema [ICD-11: MG29] REF00003271 Approved DG00829 Congestive heart failure [ICD-11: BD10-BD1Z] REF00003271 Approved DG00731 Nausea [ICD-11: MD90] REF00003269 Approved DG00576 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003268 Approved DG00577 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003268 Approved DG00902 Schizophrenia [ICD-11: 6A20] REF00003267 Approved DG00833 Hypertension [ICD-11: BA00] REF00003263 Approved DG01190 Systemic mastocytosis [ICD-11: 2A21] REF00003262 Approved DG01190 Acute myeloid leukaemia [ICD-11: 2A60] REF00003262 Approved DG01190 Acute myeloid leukaemia [ICD-11: 2A60] REF00003262 Approved DG01190 Colorectal cancer [ICD-11: 2B91] REF00003262 Approved DG01190 Chronic myelomonocytic leukaemia [ICD-11: 2A40] REF00003262 Approved DG00718 Cough [ICD-11: MD12] REF00003259 Approved DG00953 Major depressive disorder [ICD-11: 6A70-6A7Z] REF00003258 Approved DG01238 Cystic fibrosis [ICD-11: CA25] REF00003254 Approved DG00909 Diabetic complication [ICD-11: 5A2Y] REF00003252 Approved DG00909 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00003252 Approved DG01059 Polyuria [ICD-11: MF55] REF00003250 Approved DG01059 Enuresis [ICD-11: 6C00] REF00003250 Approved DG01059 Diabetes insipidus [ICD-11: 5A60-5A61] REF00003250 Approved DG00959 Hypertension [ICD-11: BA00] REF00003247 Approved DG01110 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003246 Approved DG01198 Ovarian cancer [ICD-11: 2C73] REF00003245 Approved DG01198 Ovarian cancer [ICD-11: 2C73] REF00003245 Approved DG01439 Mantle cell lymphoma [ICD-11: 2A85] REF00003239 Approved DG01080 Chronic obstructive pulmonary disease [ICD-11: CA22] REF00003238 Approved DG01080 Human immunodeficiency virus infection [ICD-11: 1C60-1C62] REF00003238 Approved DG01013 Ovarian cancer [ICD-11: 2C73] REF00003236 Approved DG01013 Lung cancer [ICD-11: 2C25] REF00003236 Approved DG01013 Testicular cancer [ICD-11: 2C80] REF00003236 Approved DG01013 Hypercalcaemia [ICD-11: 5B91] REF00003236 Approved DG01013 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003236 Approved DG01209 Breast cancer [ICD-11: 2C60] REF00003233 Approved DG00550 Cholangiocarcinoma [ICD-11: 2C12] REF00003232 Approved DG00547 Triple negative breast cancer [ICD-11: 2C60-2C6Y] REF00003232 Investigative DG00547 Renal cell carcinoma [ICD-11: 2C90] REF00003232 Investigative DG00554 Bladder cancer [ICD-11: 2C94] REF00003232 Approved DG00547 Endometrial cancer [ICD-11: 2C76] REF00003232 Investigative DG00554 Ureteral cancer [ICD-11: 2C92] REF00003232 " Phase 2" DG00550 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003232 Approved DG00554 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003232 " Phase 2" DG00554 Lymphoma [ICD-11: 2A90- 2A85] REF00003232 Phase 1/2 DG01260 Breast cancer [ICD-11: 2C60] REF00003230 Approved DG00918 Asthma [ICD-11: CA23] REF00003224 Approved DG00799 Ventricular arrhythmias [ICD-11: BC71] REF00003219 Approved DG00572 Mycoses [ICD-11: MB47] REF00003217 Approved DG00572 Fungal infection [ICD-11: 1F29-1F2F] REF00003217 Approved DG00572 Fungal infection [ICD-11: 1F29-1F2F] REF00003217 Approved DG01091 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003196 Approved DG01042 Hyperlipidaemia [ICD-11: 5C80] REF00003195 Approved DG01042 Multiple myeloma [ICD-11: 2A83] REF00003195 Approved DG00917 Helminth infection [ICD-11: 1F90] REF00003194 Approved DG00750 Anaesthesia [ICD-11: 8E22] REF00003192 Approved DG00750 Dysmenorrhea [ICD-11: GA34] REF00003192 Approved DG00861 Osteoporosis [ICD-11: FB83] REF00003187 Approved DG01146 Pain [ICD-11: MG30] REF00003185 Approved DG00647 Urinary tract infection [ICD-11: GC08] REF00003182 Approved DG00865 Trypanosomiasis [ICD-11: 1D51-1F53] REF00003181 Approved DG00768 Essential hypertension [ICD-11: BA00] REF00003179 Approved DG00816 Urinary tract infection [ICD-11: GC08] REF00003178 Approved DG00784 Cerebral vasospasm [ICD-11: BA85] REF00003170 Approved DG00831 Mydriasis [ICD-11: LA11] REF00003169 Approved DG00859 Musculoskeletal disorder [ICD-11: FA00-FC0Z] REF00003168 Approved DG00851 Depression [ICD-11: 6A70] REF00003167 Approved DG00621 Influenza A virus infection [ICD-11: 1E30-1E32] REF00003166 Approved DG00622 Influenza A virus infection [ICD-11: 1E30-1E32] REF00003166 Approved DG00737 High cholesterol level [ICD-11: 5C80] REF00003165 Approved DG00912 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003164 Approved DG00812 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003161 Approved DG00759 Heart block [ICD-11: BC63] REF00003160 Approved DG00759 Melanoma [ICD-11: 2C30] REF00003160 Approved DG01031 Ringworm infection [ICD-11: 1F28] REF00003159 Approved DG01249 Non-small-cell lung cancer [ICD-11: 2C25] REF00003157 Approved DG01249 Recurrent glioblastoma [ICD-11: 2A00] REF00003157 Approved DG01249 Hepatocellular carcinoma [ICD-11: 2C12] REF00003157 Approved DG01197 Hyperlipidaemia [ICD-11: 5C80] REF00003154 Approved DG01035 Overactive bladder [ICD-11: GC50] REF00003153 Approved DG00948 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00003152 Approved DG00635 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003149 Investigative DG00668 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003142 Approved DG01224 Dry eye disease [ICD-11: 9E1Z] REF00003139 Approved DG01224 Allergic conjunctivitis [ICD-11: 9A60] REF00003139 Approved DG01183 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003137 Approved DG01203 Ocular inflammation [ICD-11: 9C61] REF00003136 Approved DG00775 Orthostatic hypotension [ICD-11: BA21] REF00003134 Approved DG01320 Rheumatoid arthritis [ICD-11: FA20] REF00003131 Approved DG01312 Hyperuricaemia [ICD-11: 5C55] REF00003127 Approved DG00818 Respiratory tract infection [ICD-11: CA07-CA4Z] REF00003126 Approved DG00573 Intestinal strongyloidiasis due to nematode parasite [ICD-11: 1F6B] REF00003122 Approved DG00687 Malaria [ICD-11: 1F45] REF00003121 Approved DG00591 Virus infection [ICD-11: 1A24-1D9Z] REF00003117 Approved DG00590 Virus infection [ICD-11: 1A24-1D9Z] REF00003117 Approved DG01039 Anabolic metabolism [ICD-11: 5C50-5C8Z] REF00003111 Approved DG00592 Amyotrophic lateral sclerosis [ICD-11: 8B60] REF00003106 Approved DG00980 Diabetic complication [ICD-11: 5A2Y] REF00003105 Approved DG00777 Skin imperfections [ICD-11: EK71] REF00003096 Approved DG00777 Depression [ICD-11: 6A70] REF00003096 Approved DG00578 Discovery agent [ICD-11: N.A.] REF00003095 Approved DG00612 Congenital adrenal hyperplasia [ICD-11: 5A71] REF00003094 Approved DG00609 Immune System disease [ICD-11: 4A01-4B41] REF00003094 Investigative DG00610 Inflammation [ICD-11: 1A00-CA43] REF00003094 Approved DG00611 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003094 Approved DG00613 Rheumatoid arthritis [ICD-11: FA20] REF00003094 Approved DG00614 Organ transplant rejection [ICD-11: NE84] REF00003094 Approved DG00611 Spinal cord injury [ICD-11: 8C21] REF00003094 Approved DG00610 Inflammation [ICD-11: 1A00-CA43] REF00003094 Approved DG00551 Multiple sclerosis [ICD-11: 8A40] REF00003094 Approved DG00551 Arthritis [ICD-11: FA20] REF00003094 Approved DG00615 Rheumatoid arthritis [ICD-11: FA20] REF00003094 Approved DG00615 Pain [ICD-11: MG30] REF00003094 Approved DG00612 Inflammation [ICD-11: 1A00-CA43] REF00003094 Approved DG00974 Contraception [ICD-11: QA21] REF00003091 Approved DG01064 Tuberculosis [ICD-11: 1B10] REF00003085 Approved DG00679 Chemotherapy-induced nausea [ICD-11: MD90] REF00003082 Approved DG00679 Alcohol dependence [ICD-11: 6C40] REF00003082 Approved DG01267 Acute myeloid leukaemia [ICD-11: 2A60] REF00003076 Approved DG01267 Acute myeloid leukaemia [ICD-11: 2A60] REF00003076 Approved DG00580 Parkinson disease [ICD-11: 8A00] REF00003071 Approved DG00813 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003069 Approved DG01311 Schizophrenia [ICD-11: 6A20] REF00003067 Approved DG01442 Hypothyroidism [ICD-11: 5A00] REF00003060 Investigative DG00995 Osteoarthritis [ICD-11: FA00-FA05] REF00003059 Approved DG00838 Molluscum contagiosum infection [ICD-11: 1E76] REF00003058 Approved DG01309 Colon cancer [ICD-11: 2B90] REF00003052 Approved DG01307 Non-small-cell lung cancer [ICD-11: 2C25] REF00003052 Approved DG01309 Thyroid cancer [ICD-11: 2D10] REF00003052 Approved DG01309 Non-small-cell lung cancer [ICD-11: 2C25] REF00003052 Approved DG01307 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003052 Approved DG00633 Osteoarthritis [ICD-11: FA00-FA05] REF00003049 Approved DG00782 High blood pressure [ICD-11: BA00] REF00003047 Approved DG00699 Epilepsy [ICD-11: 8A60] REF00003043 Approved DG00699 Anxiety disorder [ICD-11: 6B00-6B0Z] REF00003043 Approved DG01137 Tinea pedis [ICD-11: 1F28] REF00003041 Approved DG01253 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003040 Approved DG01088 Heart arrhythmia [ICD-11: BC65] REF00003039 Approved DG00884 Asthma [ICD-11: CA23] REF00003037 Approved DG00884 Allergic rhinitis [ICD-11: CA08] REF00003037 Approved DG00819 Psoriasis vulgaris [ICD-11: EA90] REF00003031 Approved DG00804 Bacterial infection [ICD-11: 1A00-1C4Z] REF00003030 Approved DG00806 Rheumatoid arthritis [ICD-11: FA20] REF00003029 Approved DG00649 Insomnia [ICD-11: 7A00] REF00003027 Approved DG00649 Epilepsy [ICD-11: 8A60] REF00003027 Approved DG00943 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00003017 Approved DG00717 Intermittent claudication [ICD-11: BD40] REF00003012 Approved DG01006 Osteoarthritis [ICD-11: FA00-FA05] REF00003011 Approved DG00824 Alcohol dependence [ICD-11: 6C40] REF00003008 Approved DG00824 Neuropathic pain [ICD-11: 8E43] REF00003008 Approved DG00657 Flatworm infection [ICD-11: 1F70-1F86] REF00003006 Approved DG00702 Acute lymphoblastic leukaemia [ICD-11: 2A70] REF00003001 Approved DG00746 Chronic myelogenous leukaemia [ICD-11: 2A20] REF00003000 Approved DG00767 Major depressive disorder [ICD-11: 6A70-6A7Z] REF00002997 Approved DG01055 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002992 Approved DG00566 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] REF00002990 Approved DG00568 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00585 HCV 1-6 infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00564 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00564 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00585 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00600 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Investigative DG00606 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Investigative DG00602 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00584 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00604 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00603 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00607 Chronic HCV-1 infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00567 Chronic HCV-1 infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00605 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00563 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00565 Hepatitis C virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00599 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00601 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00002990 Approved DG00705 Prostate cancer [ICD-11: 2C82] REF00002983 Approved DG00574 Parkinson disease [ICD-11: 8A00] REF00002976 Approved DG00751 Friedreich's ataxia [ICD-11: 8A03] REF00002974 Approved DG00751 Cognitive impairment [ICD-11: 6D71] REF00002974 Approved DG01047 Acromegaly [ICD-11: 5A60-5A61] REF00002972 Approved DG01265 Breast cancer [ICD-11: 2C60] REF00002971 Approved DG01266 Breast cancer [ICD-11: 2C60] REF00002971 Approved DG01264 Breast cancer [ICD-11: 2C60] REF00002971 Approved DG01266 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002971 Approved DG01264 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002971 Approved DG01265 Schizophrenia [ICD-11: 6A20] REF00002971 Approved DG01265 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002971 Approved DG01368 Migraine [ICD-11: 8A80] REF00002965 Approved DG01185 Peptic ulcer [ICD-11: DA61] REF00002959 Approved DG00849 Virus infection [ICD-11: 1A24-1D9Z] REF00002957 Approved DG01239 Myelofibrosis [ICD-11: 2A20] REF00002953 Approved DG00895 Breast cancer [ICD-11: 2C60] REF00002953 Approved DG00895 Menorrhagia [ICD-11: GA20] REF00002953 Approved DG00830 Schizophrenia [ICD-11: 6A20] REF00002948 Approved DG00872 Cerebrovascular ischaemia [ICD-11: 8B1Z] REF00002946 Approved DG00979 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002938 Approved DG00543 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00002934 Approved DG00542 Acute lymphoblastic leukaemia [ICD-11: 2A70] REF00002933 Approved DG00541 Hodgkin lymphoma [ICD-11: 2B30] REF00002932 Approved DG00540 Acute myeloid leukaemia [ICD-11: 2A60] REF00002930 Approved DG00291 Discovery agent [ICD-11: N.A.] REF00002900 Investigative DG00450 Gonococcal infection [ICD-11: 1A72] REF00002898 Approved DG00290 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002898 Approved DG00231 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002883 Clinical trial DG00059 Gonococcal infection [ICD-11: 1A72] REF00002876 Approved DG00432 Discovery agent [ICD-11: N.A.] REF00002873 Investigative DG00013 Nail/perionychium infection [ICD-11: EE12] REF00002872 Phase 2 DG00245 Nail/perionychium infection [ICD-11: EE12] REF00002872 Approved DG00083 Discovery agent [ICD-11: N.A.] REF00002872 Investigative DG00234 Psychotic disorder [ICD-11: 6A20-6A25] REF00002872 Approved DG00013 Fungal infection [ICD-11: 1F29-1F2F] REF00002872 Approved DG00051 concerning food/fluid intake symptom [ICD-11: MG43] REF00002872 Approved DG00249 Hypertension [ICD-11: BA00] REF00002865 Approved DG00484 Infectious gastroenteritis/colitis [ICD-11: 1A40] REF00002844 Investigative DG00009 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002841 Investigative DG00265 Discovery agent [ICD-11: N.A.] REF00002824 Investigative DG00104 Discovery agent [ICD-11: N.A.] REF00002823 Investigative DG00211 Malaria [ICD-11: 1F45] REF00002815 Phase 2 DG00077 Malaria [ICD-11: 1F45] REF00002814 Approved DG00058 Malaria [ICD-11: 1F45] REF00002814 Approved DG00404 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] REF00002808 Approved DG00404 Gout [ICD-11: FA25] REF00002808 Approved DG00067 Bronchitis [ICD-11: CA20] REF00002804; REF00002867 Approved DG00143 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002804; REF00002867 Approved DG00203 Hyperlipoproteinaemia [ICD-11: 5C80] REF00002801; REF00002816 Approved DG00203 Blood/blood-forming organ sympton [ICD-11: MA14] REF00002801; REF00002816 Phase 3 DG00039 Irritable bowel syndrome [ICD-11: DD91] REF00002801 Approved DG00039 Rheumatoid arthritis [ICD-11: FA20] REF00002801 Approved DG00296 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002801 Approved DG00019 Vasomotor/allergic rhinitis [ICD-11: CA08] REF00002801 Approved DG00223 Malaria [ICD-11: 1F45] REF00002794 Approved DG00461 Acute diabete complication [ICD-11: 5A2Y] REF00002788 Approved DG00102 Rheumatoid arthritis [ICD-11: FA20] REF00002786 Phase 3 DG00102 Multiple sclerosis [ICD-11: 8A40] REF00002786 Approved DG00102 Hyperlipoproteinaemia [ICD-11: 5C80] REF00002786 Approved DG00102 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00002786 Phase 1 DG00116 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00002782 Phase 3 DG00109 Liver cancer [ICD-11: 2C12] REF00002781 Phase 3 DG00109 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002781 Approved DG00109 Breast cancer [ICD-11: 2C60] REF00002781 Phase 2 DG00154 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002780 Approved DG00346 Stomach cancer [ICD-11: 2B72] REF00002779 Application submitted DG00346 Breast cancer [ICD-11: 2C60] REF00002779 Approved DG00325 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00002775 Approved DG00011 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00002775 Approved DG00246 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00002775 Approved DG00197 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00002775 Approved DG00300 Colorectal cancer [ICD-11: 2B91] REF00002773 Approved DG00074 Lung cancer [ICD-11: 2C25] REF00002772 Approved DG00151 Stomach cancer [ICD-11: 2B72] REF00002764 Phase 2 DG00151 Ovarian cancer [ICD-11: 2C73] REF00002764 Phase 2 DG00151 Pancreatic cancer [ICD-11: 2C10] REF00002764 Phase 3 DG00151 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002764 Approved DG00151 Breast cancer [ICD-11: 2C60] REF00002764 Approved DG00130 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002763 Phase 2 DG00130 Pancreatic cancer [ICD-11: 2C10] REF00002763 Phase 3 DG00130 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00002763 Phase 3 DG00130 Follicular lymphoma [ICD-11: 2A80] REF00002763 Phase 3 DG00130 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00002763 Phase 3 DG00130 Mature B-cell lymphoma [ICD-11: 2A85] REF00002763 Approved DG00133 Mature B-cell lymphoma [ICD-11: 2A85] REF00002761 Approved DG00049 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002759 Approved DG00072 Melanoma [ICD-11: 2C30] REF00002757 Approved DG00023 Kaposi sarcoma [ICD-11: 2B57] REF00002756 Approved DG00023 Acute myeloid leukaemia [ICD-11: 2A60] REF00002756 Approved DG00023 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002756 Phase 2 DG00250 Gastrointestinal stromal tumour [ICD-11: 2B5B] REF00002753 Approved DG00250 Malignant digestive organ neoplasm [ICD-11: 2C11] REF00002753 Approved DG00323 Leukaemia [ICD-11: 2A60-2B33] REF00002751 Discontinued in Phase 1 DG00294 Ovarian cancer [ICD-11: 2C73] REF00002751 Approved DG00144 Mature B-cell lymphoma [ICD-11: 2A85] REF00002747 Approved DG00144 Mastocytosis [ICD-11: 2A21] REF00002747 Investigative DG00144 Myeloproliferative neoplasm [ICD-11: 2A22] REF00002747 Approved DG00144 Malignant intestine neoplasm [ICD-11: 2C0Z] REF00002747 Phase 3 DG00144 Lung cancer [ICD-11: 2C25] REF00002747 Phase 2 DG00095 Breast cancer [ICD-11: 2C60] REF00002745 Approved DG00187 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] REF00002744 Approved DG00137 Urethral cancer [ICD-11: 2C93] REF00002743 Phase 2 DG00137 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002743 Approved DG00137 Head and neck cancer [ICD-11: 2D42] REF00002743 Phase 3 DG00282 Renal cell carcinoma [ICD-11: 2C90] REF00002738 Approved DG00282 Myelodysplastic syndrome [ICD-11: 2A37] REF00002738 Phase 2 DG00282 Liver cancer [ICD-11: 2C12] REF00002738 Phase 3 DG00320 Inborn energy metabolism error [ICD-11: 5C53] REF00002734 Phase 3 DG00320 Insulin-resistance syndrome [ICD-11: 5A44] REF00002734 Phase 4 DG00320 Idiopathic interstitial pneumonitis [ICD-11: CB03] REF00002734 Phase 1 DG00444 Glanders [ICD-11: 1B92] REF00002729 Approved DG00153 Brain cancer [ICD-11: 2A00] REF00002727 Approved DG00228 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002724 Approved DG00340 Colorectal cancer [ICD-11: 2B91] REF00002723 Approved DG00108 Mature B-cell lymphoma [ICD-11: 2A85] REF00002717 Approved DG00314 Adrenal cancer [ICD-11: 2D11] REF00002709 Approved DG00329 Hypo-thyroidism [ICD-11: 5A00] REF00002705 Approved DG00099 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002700 Approved DG00053 Lung cancer [ICD-11: 2C25] REF00002690 Phase 2 DG00053 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002690 Phase 1/2 DG00050 Lung cancer [ICD-11: 2C25] REF00002690 Approved DG00163 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002688 Approved DG00193 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002688 Approved DG00037 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002688 Approved DG00227 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002688 Approved DG00048 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00002688 Phase 3 DG00048 Urinary tract infection [ICD-11: GC08] REF00002688 Approved DG00328 Respiratory infection [ICD-11: CA07-CA4Z] REF00002688 Phase 4 DG00299 Acute bronchitis [ICD-11: CA42] REF00002687 Approved DG00195 Renal cell carcinoma [ICD-11: 2C90] REF00002686 Phase 2 DG00337 Breast cancer [ICD-11: 2C60] REF00002681 Approved DG00266 Mature B-cell lymphoma [ICD-11: 2A85] REF00002673 Approved DG00266 Multiple myeloma [ICD-11: 2A83] REF00002673 Approved DG00266 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00002673 Phase 3 DG00014 Discovery agent [ICD-11: N.A.] REF00002651 Investigative DG00148 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002642 Approved DG00159 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002638 Approved DG00199 Eczema [ICD-11: EA80-EA89] REF00002633 Phase 1 DG00199 Atopic eczema [ICD-11: EA80] REF00002633 Phase 1 DG00199 Postoperative inflammation [ICD-11: 1A00-CA43] REF00002633 Approved DG00200 Rheumatoid arthritis [ICD-11: FA20] REF00002633 Approved DG00267 Vitreoretinopathy [ICD-11: 9B78] REF00002618 Phase 3 DG00267 Prostate cancer [ICD-11: 2C82] REF00002618 Investigative DG00267 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002618 Phase 3 DG00267 Leukaemia [ICD-11: 2A60-2B33] REF00002618 Approved DG00267 Rheumatoid arthritis [ICD-11: FA20] REF00002618 Phase 1 DG00330 Lung cancer [ICD-11: 2C25] REF00002616 Registered DG00101 Pancreatic cancer [ICD-11: 2C10] REF00002616 Phase 3 DG00101 Lung cancer [ICD-11: 2C25] REF00002616 Approved DG00101 Colon cancer [ICD-11: 2B90] REF00002616 Phase 2 DG00544 Pancreatic cancer [ICD-11: 2C10] REF00002616 Phase 3 DG00544 Lung cancer [ICD-11: 2C25] REF00002616 Approved DG00544 Colon cancer [ICD-11: 2B90] REF00002616 Phase 2 DG00204 Breast cancer [ICD-11: 2C60] REF00002614 Approved DG00087 Preterm labour/delivery [ICD-11: JB00] REF00002604 Approved DG00087 Contraceptive management [ICD-11: QA21] REF00002604 Phase 3 DG00007 Myeloproliferative neoplasm [ICD-11: 2A22] REF00002561 Approved DG00174 Myeloproliferative neoplasm [ICD-11: 2A22] REF00002561 Approved DG00174 Multiple myeloma [ICD-11: 2A83] REF00002561 Phase 2 DG00338 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00002554 Approved DG00338 Pemphigus [ICD-11: EB40] REF00002554 Phase 3 DG00297 Malignant digestive organ neoplasm [ICD-11: 2C11] REF00002542 Approved DG00297 Breast cancer [ICD-11: 2C60] REF00002542 Approved DG00297 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002542 Approved DG00274 Epilepsy/seizure [ICD-11: 8A61-8A6Z] REF00002541 Phase 3 DG00327 Cardiovascular disease [ICD-11: BA00-BE2Z] REF00002541 Approved DG00274 Mood/affect symptom [ICD-11: MB24] REF00002541 Approved DG00002 Liver cancer [ICD-11: 2C12] REF00002538 Phase 3 DG00002 Multiple myeloma [ICD-11: 2A83] REF00002538 Approved DG00125 Malaria [ICD-11: 1F45] REF00002531; REF00002793; REF00002805; REF00002814 Approved DG00232 Malaria [ICD-11: 1F45] REF00002531; REF00002793; REF00002805; REF00002814 Approved DG00119 Discovery agent [ICD-11: N.A.] REF00002517 Investigative DG00317 Discovery agent [ICD-11: N.A.] REF00002504 Investigative DG00032 Ovarian cancer [ICD-11: 2C73] REF00002496 Approved DG00032 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002496 Approved DG00032 Lung cancer [ICD-11: 2C25] REF00002496 Phase 1 DG00305 Melanoma [ICD-11: 2C30] REF00002491 Approved DG00335 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002472 Approved DG00115 Breast cancer [ICD-11: 2C60] REF00002460 Approved DG00165 Type 2 diabetes mellitus [ICD-11: 5A11] REF00002447 Approved DG00261 Periodontal disease [ICD-11: DA0C] REF00002431 Approved DG00261 Gingival/edentulous alveolar ridge disorder [ICD-11: DA0D] REF00002431 Approved DG00106 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002431 Approved DG00261 Diabetic foot ulcer [ICD-11: BD54] REF00002431 Phase 2 DG00090 Discovery agent [ICD-11: N.A.] REF00002428 Investigative DG00405 Dental disease [ICD-11: DA08] REF00002418 Approved DG00214 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002406 Phase 2 DG00214 Osteosarcoma [ICD-11: 2B51] REF00002406 Phase 2 DG00214 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00002406 Phase 2 DG00132 Cough [ICD-11: MD12] REF00002396 Approved DG00158 Bowel habit change [ICD-11: ME05] REF00002396 Approved DG00198 Motor neuron disease [ICD-11: 8B60] REF00002391 Preclinical DG00118 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002355 Approved DG00107 Candidosis [ICD-11: 1F23] REF00002346 Phase 3 DG00107 Aspergillosis [ICD-11: 1F20] REF00002346 Phase 3 DG00036 Candidosis [ICD-11: 1F23] REF00002342 Phase 3 DG00079 Candidosis [ICD-11: 1F23] REF00002342 Approved DG00185 Epilepsy/seizure [ICD-11: 8A61-8A6Z] REF00002342 Approved DG00306 Melanoma [ICD-11: 2C30] REF00002323 Approved DG00020 Brain cancer [ICD-11: 2A00] REF00002321 Approved DG00020 Liver cancer [ICD-11: 2C12] REF00002321 Approved DG00332 Renal cell carcinoma [ICD-11: 2C90] REF00002310 Approved DG00010 Influenza [ICD-11: 1E30] REF00002302 Phase 2 DG00293 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002294 Approved DG00026 Liver disease [ICD-11: DB90-DB9Z] REF00002272 Phase 2/3 DG00052 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002268 Approved DG00103 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002220 Phase 3 DG00434 Myelodysplastic syndrome [ICD-11: 2A37] REF00002212 Approved DG00331 Breast cancer [ICD-11: 2C60] REF00002205 Phase 2 DG00331 Renal cell carcinoma [ICD-11: 2C90] REF00002205 Phase 3 DG00331 Endometrial cancer [ICD-11: 2C76] REF00002205 Phase 2 DG00429 Psoriasis [ICD-11: EA90] REF00002166 Phase 2/3 DG00429 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00002166 Phase 3 DG00429 Acute myeloid leukaemia [ICD-11: 2A60] REF00002166 Approved (orphan drug) DG00192 Mature B-cell lymphoma [ICD-11: 2A85] REF00002156 Approved DG00262 Malaria [ICD-11: 1F45] REF00002143 Approved DG00171 Diabetes mellitus [ICD-11: 5A10] REF00002121 Investigative DG00295 Fungal infection [ICD-11: 1F29-1F2F] REF00002113 Approved DG00006 Discovery agent [ICD-11: N.A.] REF00002102 Investigative DG00196 Discovery agent [ICD-11: N.A.] REF00002095 Investigative DG00080 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002077 Approved DG00080 Dissociative neurological symptom disorder [ICD-11: 6B60] REF00002077 Investigative DG00021 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002069; REF00002804 Approved DG00062 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002069; REF00002804 Approved DG00339 Breast cancer [ICD-11: 2C60] REF00002067 Phase 3 DG00342 Breast cancer [ICD-11: 2C60] REF00002067 Approved DG00268 Hair/hair growth developmental defect [ICD-11: LC30] REF00002059 Approved DG00322 Brain cancer [ICD-11: 2A00] REF00002049 Phase 2 DG00045 Multiple myeloma [ICD-11: 2A83] REF00002046 Approved DG00045 Transplant rejection [ICD-11: NE84] REF00002046 Approved DG00045 Hydrocephalus [ICD-11: 8D64] REF00002046 Phase 1/2 DG00292 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00002044 Investigative DG00292 Skin disease [ICD-11: EA00-EM0Z] REF00002044 Investigative DG00066 Bacterial infection [ICD-11: 1A00-1C4Z] REF00002037 Approved DG00255 Discovery agent [ICD-11: N.A.] REF00002022 Investigative DG00281 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001997 Phase 2 DG00336 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00001993 Investigative DG00175 Mycobacterium infection [ICD-11: 1B10-1B21] REF00001993 Phase 2 DG00175 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001993 Approved DG00270 Lung cancer [ICD-11: 2C25] REF00001979 Approved DG00253 Lymphoma [ICD-11: 2A90- 2A85] REF00001979 Investigative DG00425 Discovery agent [ICD-11: N.A.] REF00001956 Investigative DG00419 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001956 Approved DG00421 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001956 Approved DG00016 Sepsis [ICD-11: 1G40] REF00001956 Approved DG00088 Colorectal cancer [ICD-11: 2B91] REF00001950 Approved DG00341 Head and neck cancer [ICD-11: 2D42] REF00001943 Phase 2 DG00341 Colorectal cancer [ICD-11: 2B91] REF00001943 Approved DG00254 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00001927 Phase 1/2 DG00254 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001927 Approved DG00213 Renal cell carcinoma [ICD-11: 2C90] REF00001925 Phase 3 DG00213 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001925 Phase 2 DG00092 Urinary tract infection [ICD-11: GC08] REF00001908 Approved DG00240 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001905 Approved DG00117 Rosacea [ICD-11: ED90] REF00001892 Phase 2 DG00256 Glanders [ICD-11: 1B92] REF00001892 Approved DG00201 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001892 Approved DG00117 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001892 Approved DG00235 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001872; REF00002826 Approved DG00084 Aspergillosis [ICD-11: 1F20] REF00001864 Approved DG00216 Lung cancer [ICD-11: 2C25] REF00001844; REF00001900; REF00002211 Phase 3 DG00312 Schizophrenia [ICD-11: 6A20] REF00001786 Approved DG00034 Prostate cancer [ICD-11: 2C82] REF00001776 Approved DG00247 Prostate cancer [ICD-11: 2C82] REF00001776 Approved DG00167 Malaria [ICD-11: 1F45] REF00001754 Approved DG00324 Leukaemia [ICD-11: 2A60-2B33] REF00001753 Approved DG00128 Peritoneal cancer [ICD-11: 2C51] REF00001742 Phase 3 DG00128 Idiopathic interstitial pneumonitis [ICD-11: CB03] REF00001742 Approved DG00128 Ovarian cancer [ICD-11: 2C73] REF00001742 Phase 2 DG00128 Lung cancer [ICD-11: 2C25] REF00001742 Phase 3 DG00128 Colorectal cancer [ICD-11: 2B91] REF00001742 Approved DG00071 Lung cancer [ICD-11: 2C25] REF00001737 Approved DG00017 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001733 Approved DG00275 Multiple myeloma [ICD-11: 2A83] REF00001727 Approved DG00189 COVID-19 [ICD-11: 1D92] REF00001706 Phase 1 DG00124 Gout [ICD-11: FA25] REF00001706 Approved DG00287 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001700 Approved DG00091 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001700 Approved DG00272 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001700 Approved DG00248 COVID-19 [ICD-11: 1D92] REF00001696 Investigative DG00344 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001693 Phase 2 DG00344 Renal cell carcinoma [ICD-11: 2C90] REF00001693 Phase 3 DG00344 Prostate cancer [ICD-11: 2C82] REF00001693 Phase 2 DG00344 Ovarian cancer [ICD-11: 2C73] REF00001693 Phase 2 DG00344 Lung cancer [ICD-11: 2C25] REF00001693 Phase 3 DG00344 Liver cancer [ICD-11: 2C12] REF00001693 Phase 3 DG00344 Esophageal cancer [ICD-11: 2B70] REF00001693 Phase 3 DG00344 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00001693 Application submitted DG00344 Colorectal cancer [ICD-11: 2B91] REF00001693 Phase 3 DG00344 Breast cancer [ICD-11: 2C60] REF00001693 Phase 3 DG00344 Melanoma [ICD-11: 2C30] REF00001693 Approved DG00140 Corneal disease [ICD-11: 9A76-9A78] REF00001692 Approved DG00438 Breast cancer [ICD-11: 2C60] REF00001681 Approved DG00136 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] REF00001674 Approved DG00168 Sensation disturbance [ICD-11: MB40] REF00001663 Approved DG00168 Pain [ICD-11: MG30] REF00001663 Phase 3 DG00168 Chronic pain [ICD-11: MG30] REF00001663 Phase 3 DG00112 Mature B-cell lymphoma [ICD-11: 2A85] REF00001662 Approved DG00222 Aspergillosis [ICD-11: 1F20] REF00001657 Approved DG00260 Melanoma [ICD-11: 2C30] REF00001649 Phase 1 DG00273 Osteosarcoma [ICD-11: 2B51] REF00001639; REF00002251; REF00002276 Phase 2 DG00273 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001639; REF00002251; REF00002276 Approved DG00138 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001635 Phase 3 DG00289 Discovery agent [ICD-11: N.A.] REF00001634 Investigative DG00022 Contraceptive management [ICD-11: QA21] REF00001625 Approved DG00086 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001622 Approved DG00029 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001620 Approved DG00286 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001619 Approved DG00202 Prostate cancer [ICD-11: 2C82] REF00001617 Phase 3 DG00202 Pancreatic cancer [ICD-11: 2C10] REF00001617 Phase 3 DG00202 Ovarian cancer [ICD-11: 2C73] REF00001617 Approved DG00403 Breast cancer [ICD-11: 2C60] REF00001616 Approved DG00044 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001611 Approved DG00229 Lung cancer [ICD-11: 2C25] REF00001607 Approved DG00229 Melanoma [ICD-11: 2C30] REF00001607 Phase 3 DG00042 Brain cancer [ICD-11: 2A00] REF00001578 Phase 2 DG00042 Basal cell carcinoma [ICD-11: 2C32] REF00001578 Approved DG01586 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001577 Phase 1/2 DG01586 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001577 Phase 1/2 DG01586 Chronic lymphocytic leukaemia [ICD-11: 2A82] REF00001577 Phase 1/2 DG01579 Myelofibrosis [ICD-11: 2A20] REF00001577 Phase 1 DG00280 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001567 Phase 2 DG00206 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001567 Discontinued in Phase 1/2 DG00177 Renal cell carcinoma [ICD-11: 2C90] REF00001567 Approved DG00208 Renal cell carcinoma [ICD-11: 2C90] REF00001567 Approved DG00321 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001566; REF00002560 Phase 1 DG00225 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001565; REF00001977 Approved DG00225 Cystic fibrosis [ICD-11: CA25] REF00001565; REF00001977 Phase 2 DG00225 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00001565; REF00001977 Approved DG00225 Digestive organ benign neoplasm [ICD-11: 2E92] REF00001565; REF00001977 Phase 1 DG00301 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] REF00001539 Investigative DG00085 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001539 Approved DG00301 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001539 Approved DG00284 Breast cancer [ICD-11: 2C60] REF00001518; REF00001844 Approved DG00284 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001518; REF00001844 Phase 2 DG00176 Mycosis fungoides [ICD-11: 2B01] REF00001479 Approved DG00304 Pleural mesothelioma [ICD-11: 2C26] REF00001479 Approved DG00015 Mature B-cell lymphoma [ICD-11: 2A85] REF00001463 Approved DG00191 Malaria [ICD-11: 1F45] REF00001447; REF00002814 Approved DG00309 Lymphoma [ICD-11: 2A90- 2A85] REF00001435 Phase 2 DG00316 Discovery agent [ICD-11: N.A.] REF00001435 Investigative DG00209 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001425 Approved DG00098 Malaria [ICD-11: 1F45] REF00001416 Approved DG00134 Mature B-cell lymphoma [ICD-11: 2A85] REF00001406 Approved DG00040 Acute myeloid leukaemia [ICD-11: 2A60] REF00001406 Approved DG00134 Crohn disease [ICD-11: DD70] REF00001406 Phase 4 DG00055 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001395; REF00001801; REF00002839 Approved DG00343 Pancreatic cancer [ICD-11: 2C10] REF00001382 Phase 1 DG00343 Mature B-cell lymphoma [ICD-11: 2A85] REF00001382 Phase 3 DG00056 Lung cancer [ICD-11: 2C25] REF00001377 Approved DG00041 Malaria [ICD-11: 1F45] REF00001376; REF00002455 Approved DG00244 Breast cancer [ICD-11: 2C60] REF00001374 Phase 3 DG00073 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001362 Approved DG00181 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001358 Approved DG00333 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001358 Approved DG00178 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001358 Approved DG00333 Coronavirus infection [ICD-11: 1D92] REF00001358 Approved DG00334 Melanoma [ICD-11: 2C30] REF00001349 Phase 2 DG00334 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] REF00001349 Phase 3 DG00334 Ovarian cancer [ICD-11: 2C73] REF00001349 Phase 3 DG00334 Lung cancer [ICD-11: 2C25] REF00001349 Phase 3 DG00334 Breast cancer [ICD-11: 2C60] REF00001349 Phase 3 DG00081 Hodgkin lymphoma [ICD-11: 2B30] REF00001330 Approved DG00241 Multiple myeloma [ICD-11: 2A83] REF00001318; REF00001880 Approved DG00422 Breast cancer [ICD-11: 2C60] REF00001301; REF00001681 Approved DG00397 Breast cancer [ICD-11: 2C60] REF00001301; REF00001681 Approved DG00218 Myeloproliferative neoplasm [ICD-11: 2A22] REF00001291 Approved DG00277 Renal cell carcinoma [ICD-11: 2C90] REF00001287 Phase 3 DG00277 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001287 Phase 2 DG00277 Mature T-cell lymphoma [ICD-11: 2A90] REF00001287 Phase 2 DG00277 Gynecologic cancer [ICD-11: 2F33-2F76] REF00001287 Phase 2 DG00277 Follicular lymphoma [ICD-11: 2A80] REF00001287 Phase 3 DG00277 Diffuse large B-cell lymphoma [ICD-11: 2A81] REF00001287 Phase 2 DG00277 Breast cancer [ICD-11: 2C60] REF00001287 Phase 2 DG00277 Acute myeloid leukaemia [ICD-11: 2A60] REF00001287 Phase 2 DG00024 Virus infection [ICD-11: 1A24-1D9Z] REF00001267 Investigative DG00141 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001267 Approved DG00226 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001267 Approved DG00075 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001267 Approved DG00024 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001267 Approved DG00315 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001267 Approved DG00269 Pain [ICD-11: MG30] REF00001267 Investigative DG00269 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001267 Approved DG00236 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001260 Approved DG00093 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001260 Approved DG00212 Menopausal disorder [ICD-11: GA30] REF00001258 Phase 2/3 DG00212 Prostate cancer [ICD-11: 2C82] REF00001258 Phase 2 DG00164 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001246 Approved DG00164 Multiple sclerosis [ICD-11: 8A40] REF00001246 Phase 3 DG00146 Infectious meningitis [ICD-11: 1D01] REF00001245 Investigative DG00146 Anaerobic bacterial infection [ICD-11: 1A00-1A09] REF00001245 Approved DG00076 Clostridium difficile enterocolitis [ICD-11: 1A04] REF00001245 Approved DG00230 Breast cancer [ICD-11: 2C60] REF00001231; REF00001598 Approved DG00326 Discovery agent [ICD-11: N.A.] REF00001212 Investigative DG00031 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001188; REF00002480; REF00002512 Approved DG00120 Unspecific body region injury [ICD-11: ND56] REF00001187 Approved DG00120 Skin postprocedural disorder [ICD-11: EL8Y] REF00001187 Phase 2 DG00215 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] REF00001181 Approved DG00479 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001181 Approved DG00166 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00001139; REF00001651; REF00002436 Approved DG00157 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00001139; REF00001651; REF00002436 Approved DG00008 Discovery agent [ICD-11: N.A.] REF00001139; REF00001651; REF00002436 Investigative DG00210 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00001139; REF00001651; REF00002436 Approved DG00224 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00001135 Investigative DG00319 Escherichia coli intestinal infection [ICD-11: 1A03] REF00001130 Phase 2 DG00257 Urinary tract infection [ICD-11: GC08] REF00001130 Approved DG00003 Colorectal cancer [ICD-11: 2B91] REF00001109 Approved DG00003 Breast cancer [ICD-11: 2C60] REF00001109 Phase 3 DG00060 Pneumonia [ICD-11: CA40] REF00001098 Approved DG00082 Metastatic tumour [ICD-11: 2D50-2E2Z] REF00001082 Phase 2 DG00082 Metastatic meninges neoplasm [ICD-11: 2D51] REF00001082 Phase 2 DG00082 Brain cancer [ICD-11: 2A00] REF00001082 Phase 2 DG00082 Cystic/dysplastic kidney disease [ICD-11: GB8Y] REF00001082 Phase 2 DG00082 Lung cancer [ICD-11: 2C25] REF00001082 Phase 2 DG00122 Clostridium difficile enterocolitis [ICD-11: 1A04] REF00001072 Phase 2 DG00179 Malignant haematopoietic neoplasm [ICD-11: 2B33] REF00001069 Approved DG00096 Acute myeloid leukaemia [ICD-11: 2A60] REF00001061; REF00001171 Phase 3 DG00096 Leukaemia [ICD-11: 2A60-2B33] REF00001061; REF00001171 Phase 3 DG00205 Breast cancer [ICD-11: 2C60] REF00001055 Phase 2 DG00063 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001049; REF00001236 Approved DG00303 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001044 Withdrawn from market DG00030 Heart failure [ICD-11: BD10] REF00001043 Approved DG00030 Cardiac arrhythmia [ICD-11: BC9Z] REF00001043 Approved DG00121 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001034 Approved DG00068 Bacterial infection [ICD-11: 1A00-1C4Z] REF00001005 Approved DG00068 Alcoholic liver disease [ICD-11: DB94] REF00001005 Approved DG00068 Acute/subacute hepatic failure [ICD-11: DB91] REF00001005 Approved DG00239 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000993 Approved DG00069 Colorectal cancer [ICD-11: 2B91] REF00000984; REF00002238 Investigative DG00069 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00000984; REF00002238 Approved DG00180 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000976 Approved DG00100 Malaria [ICD-11: 1F45] REF00000942 Approved DG00345 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000923 Approved DG00126 Fungal infection [ICD-11: 1F29-1F2F] REF00000913 Approved DG00142 Urinary tract infection [ICD-11: GC08] REF00000904 Approved DG00027 Acute myeloid leukaemia [ICD-11: 2A60] REF00000893; REF00001636 Approved DG00027 Acne vulgaris [ICD-11: ED80] REF00000893; REF00001636 Approved DG00078 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000882; REF00001021; REF00001203; REF00001517; REF00001588; REF00002809 Approved DG00018 Rectum cancer [ICD-11: 2B92] REF00000874 Approved DG00001 Malaria [ICD-11: 1F45] REF00000872 Approved DG00001 Trypanosomiasis [ICD-11: 1D51-1F53] REF00000872 Investigative DG00238 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000839 Approved DG00233 Bowel habit change [ICD-11: ME05] REF00000817 Approved DG00161 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00000814 Discontinued in Phase 3 DG00276 Discovery agent [ICD-11: N.A.] REF00000811 Approved DG00043 Syphilis [ICD-11: 1A61-1A6Z] REF00000798 Approved DG00105 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00000790 Approved DG00105 Hepatitis virus infection [ICD-11: 1E50-1E51] REF00000790 Approved DG00400 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000775; REF00002858 Approved DG00094 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000775; REF00002858 Approved DG00170 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000770 Approved DG00288 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000770 Approved DG00149 Vasomotor/allergic rhinitis [ICD-11: CA08] REF00000756 Approved DG00184 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00000749; REF00001122; REF00002827 Withdrawn from market DG00129 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000749; REF00001122; REF00002827 Approved DG00057 Amoebiasis [ICD-11: 1A36] REF00000730 Approved DG00162 Schizophrenia [ICD-11: 6A20] REF00000724 Approved DG00025 Schizophrenia [ICD-11: 6A20] REF00000724 Approved DG00033 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000713; REF00001092 Approved DG00318 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000713; REF00001092 Approved DG00402 Nasopharyngeal cancer [ICD-11: 2B6B] REF00000712 Investigative DG00054 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000712 Approved DG00402 Lung cancer [ICD-11: 2C25] REF00000712 Phase 3 DG00441 Irritable bowel syndrome [ICD-11: DD91] REF00000712 Approved DG00414 Acquired methaemoglobinaemia [ICD-11: 3A93] REF00000712 Approved DG00433 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00000712 Phase 1 DG00396 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00000708 Terminated DG00169 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000705 Approved DG00012 Fungal infection [ICD-11: 1F29-1F2F] REF00000701 Approved DG00413 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000690 Approved DG00415 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] REF00000690 Approved DG00413 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] REF00000690 Approved DG00089 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00000686 Approved DG00035 Urinary tract infection [ICD-11: GC08] REF00000682; REF00002884 Approved DG00308 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000682; REF00002884 Approved DG00220 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000682; REF00002884 Approved DG00183 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000682; REF00002884 Approved DG00278 Fungal infection [ICD-11: 1F29-1F2F] REF00000680 Approved DG00263 Mycobacterium infection [ICD-11: 1B10-1B21] REF00000679 Investigative DG00263 Crohn disease [ICD-11: DD70] REF00000679 Approved DG00219 Pneumonia [ICD-11: CA40] REF00000679 Approved DG00065 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00000676 Withdrawn from market DG00065 Fungal infection [ICD-11: 1F29-1F2F] REF00000676 Approved DG00221 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000672; REF00000737; REF00001114; REF00002840; REF00002843; REF00002870 Approved DG00264 Endocarditis [ICD-11: BB40-BA42] REF00000666 Approved DG00131 Fungal infection [ICD-11: 1F29-1F2F] REF00000665; REF00002891 Approved DG00445 Bowel habit change [ICD-11: ME05] REF00000663 Approved DG00186 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] REF00000662; REF00002902 Approved DG00047 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000662; REF00002902 Approved DG00252 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000656 Approved DG00145 Gram-negative bacterial infection [ICD-11: 1B74-1G40] REF00000654; REF00002899 Phase 1 DG00310 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000654; REF00002899 Approved DG00188 Discovery agent [ICD-11: N.A.] REF00000654; REF00002899 Investigative DG00139 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000649; REF00001399 Approved DG00182 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000645; REF00000739; REF00002344; REF00002874; REF00002890 Approved DG00259 Lyme borreliosis [ICD-11: 1C1G] REF00000641 Approved DG00259 Bronchitis [ICD-11: CA20] REF00000641 Approved DG00259 Acne vulgaris [ICD-11: ED80] REF00000641 Approved DG00147 Fungal infection [ICD-11: 1F29-1F2F] REF00000632 Approved DG00251 Acne vulgaris [ICD-11: ED80] REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 Approved DG00038 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 Approved DG00237 Gram-positive bacterial infection [ICD-11: 1B74-1F40] REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 Approved DG00313 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 Approved DG00127 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000619; REF00002749; REF00002842; REF00002895; REF00002908 Approved DG00271 General pain disorder [ICD-11: 8E43] REF00000618 Approved DG00279 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] REF00000610 Approved DG00258 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000608 Approved DG00258 Malaria [ICD-11: 1F45] REF00000608 Investigative DG00004 Urinary tract infection [ICD-11: GC08] REF00000601 Approved DG00302 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000599 Phase 1 DG00242 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000593; REF00000748; REF00002853 Approved DG00190 Retinopathy [ICD-11: 9B71] REF00000580 Investigative DG00064 Mycobacterium infection [ICD-11: 1B10-1B21] REF00000580 Approved DG00064 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] REF00000580 Approved DG00190 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] REF00000580 Approved DG00173 Urinary tract infection [ICD-11: GC08] REF00000572; REF00002090 Approved DG00173 Prostate disease [ICD-11: GA91] REF00000572; REF00002090 Approved DG00173 Bronchitis [ICD-11: CA20] REF00000572; REF00002090 Approved DG00173 Pancreatic cancer [ICD-11: 2C10] REF00000572; REF00002090 Phase 3 DG00156 Pneumonia [ICD-11: CA40] REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 Phase 3 DG00156 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 Phase 3 DG00207 Respiratory infection [ICD-11: CA07-CA4Z] REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 Approved DG00283 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 Approved DG00311 Bacterial infection [ICD-11: 1A00-1C4Z] REF00000540; REF00000570; REF00000800; REF00001475; REF00001615; REF00001744 Approved DG01500 Malaria [ICD-11: 1F45] REF00000491 Discontinued in Phase 1 DG00618 Thyroid cancer [ICD-11: 2D10] REF00003237 Phase 1 DG00618 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003237 Phase 2 DG00618 Renal cell carcinoma [ICD-11: 2C90] REF00003237 Phase 3 DG00618 Ovarian cancer [ICD-11: 2C73] REF00003237 Phase 2 DG00618 Non-small-cell lung cancer [ICD-11: 2C25] REF00003237 Phase 1 DG00618 Melanoma [ICD-11: 2C30] REF00003237 Phase 2 DG00618 Hepatocellular carcinoma [ICD-11: 2C12] REF00003237 Phase 1 DG00618 Hepatocellular carcinoma [ICD-11: 2C12] REF00003237 Phase 2 DG00722 Trypanosomiasis [ICD-11: 1D51-1F53] REF00003654 Phase 2 DG00722 African trypanosomiasis [ICD-11: 1F51] REF00003654 Approved DG00770 Dizziness [ICD-11: MB48] REF00003754 Phase 1 DG00869 Liver disease [ICD-11: DB90-DB9Z] REF00002964 Approved DG01052 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003380 Phase 1/2 DG01090 Type-2 diabetes [ICD-11: 5A11] REF00003829 Approved DG01090 Type-2 diabetes [ICD-11: 5A11] REF00003829 Phase 3 DG01090 Type-2 diabetes [ICD-11: 5A11] REF00003829 Phase 3 DG01090 Peripheral arterial disease [ICD-11: BD4Z] REF00003829 Phase 1 DG01248 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003318 Patented DG01248 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003318 Phase 1 DG01248 Non-small cell lung cancer [ICD-11: 2C25] REF00003318 Investigative DG01248 Neuroblastoma [ICD-11: 2A00] REF00003318 Investigative DG01248 Mammary analogue secretory carcinoma [ICD-11: 2C60-2C6Y] REF00003318 Investigative DG01248 Colorectal cancer [ICD-11: 2B91] REF00003318 Approved DG01248 Colorectal cancer [ICD-11: 2B91] REF00003318 Investigative DG01285 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003586 Phase 1/2 DG01285 Small-cell lung cancer [ICD-11: 2C25] REF00003586 Phase 2 DG01285 Ovarian cancer [ICD-11: 2C73] REF00003586 Phase 2 DG01285 leukaemia [ICD-11: 2A60-2B33] REF00003586 Phase 1 DG01285 leukaemia [ICD-11: 2A60-2B33] REF00003586 Phase 1 DG01285 Endometrial cancer [ICD-11: 2C76] REF00003586 Phase 2 DG01303 Ventilator-associated pneumonia [ICD-11: PK80-PK81] REF00003034 Phase 2 DG01303 Urinary tract infection [ICD-11: GC08] REF00003034 Phase 4 DG01303 Hospital-acquired pneumonia [ICD-11: CA40] REF00003034 Approved DG01303 Healthcare-associated pneumonia [ICD-11: CA00-CA40] REF00003034 Phase 1 DG01477 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004478 Phase 1 DG01477 Non-small-cell lung cancer [ICD-11: 2C25] REF00004478 Phase 1 DG01477 Nasopharyngeal carcinoma [ICD-11: 2B6B] REF00004478 Investigative DG01498 Discovery agent [ICD-11: N.A.] REF00004487 Terminated DG01501 Rheumatoid arthritis [ICD-11: FA20] REF00004196 Discontinued in Phase 2 DG01509 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004088 Phase 1 DG01513 Metastatic colorectal cancer [ICD-11: 2D85] REF00003968 Phase 2 DG01516 Breast cancer [ICD-11: 2C60] REF00003969 Approved DG01523 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004033 Phase 1 DG01530 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003965 Investigative DG01539 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004038 Phase 1 DG01555 Triple negative breast cancer [ICD-11: 2C60-2C6Y] REF00004276 Phase 3 DG01555 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004276 Phase 1 DG01557 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004037 Phase 2 DG01562 Obesity [ICD-11: 5B81] REF00003900 Phase 2 DG01565 Thrombosis [ICD-11: DB61-GB90] REF00004551 Approved DG01571 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004294 Investigative DG01571 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004294 Phase 1 DG01571 Biliary tract cancer [ICD-11: 2C15] REF00004294 Phase 2 DG01572 Lung cancer [ICD-11: 2C25] REF00004520 Phase 3 DG01573 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004527 Investigative DG01575 Myeloproliferative neoplasm [ICD-11: 2A22] REF00004327 Approved DG01575 Breast cancer [ICD-11: 2C60] REF00004327 Phase 1 DG01581 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004362 Approved DG01581 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004362 Phase 1 DG01581 Malignant mesothelioma [ICD-11: 2C26] REF00004362 Application submitted DG01583 Rectal adenocarcinoma [ICD-11: 2B92] REF00003901 Investigative DG01583 Nasopharyngeal carcinoma [ICD-11: 2B6B] REF00003901 Phase 2 DG01584 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003999 Phase 1 DG01590 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004449 Phase 1 DG01599 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004377 Investigative DG01599 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004377 Phase 1 DG01616 Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] REF00004194 Investigative DG01616 Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] REF00004194 Investigative DG01616 Lymphangioleiomyomatosis [ICD-11: CB07] REF00004194 Phase 1/2 DG01620 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004532 Phase 2 DG01623 Systemic mastocytosis [ICD-11: 2A21] REF00003968 Investigative DG01623 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003968 Investigative DG01623 Glioma [ICD-11: 2A00] REF00003968 Phase 2 DG01623 Gastrointestinal stromal tumour [ICD-11: 2B5B] REF00003968 Approved DG01628 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004139 Phase 3 DG01637 Discovery agent [ICD-11: N.A.] REF00003917 Approved DG01656 Non-small-cell lung cancer [ICD-11: 2C25] REF00004143 Phase 2 DG01663 Colorectal cancer [ICD-11: 2B91] REF00004397 Phase 2 DG01664 Non-small-cell lung cancer [ICD-11: 2C25] REF00004497 Phase 2 DG01664 Liver cancer [ICD-11: 2C12] REF00004497 Approved DG01814 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004205 Phase 1 DG01814 Osteosarcoma [ICD-11: 2B51] REF00004205 Phase 2 DG01835 Malaria [ICD-11: 1F45] REF00003895 Approved DG01846 Attention deficit hyperactivity disorder [ICD-11: 6A05] REF00004336 Phase 3 DG01850 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004554 Approved DG01854 Graves disease [ICD-11: 5A02] REF00004497 Approved DG01854 Diabetic macular edema [ICD-11: 9B71] REF00004497 Investigative DG01857 Multiple myeloma [ICD-11: 2A83] REF00003956 Phase 1 DG01868 Hyperlipidaemia [ICD-11: 5C80] REF00004448 Approved DG01869 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00003948 Phase 1 DG01869 Hepatocellular carcinoma [ICD-11: 2C12] REF00003948 Phase 2 DG01869 Head and neck cancer [ICD-11: 2D42] REF00003948 Phase 2 DG01871 Breast cancer [ICD-11: 2C60] REF00004016 Phase 2 DG01873 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004191 Phase 1 DG01876 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004353 Phase 1 DG01877 Haematological malignancy [ICD-11: 2B33] REF00004187 Phase 3 DG01879 Thyroid cancer [ICD-11: 2D10] REF00004300 Phase 3 DG01879 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004300 Phase 1/2 DG01879 Non-small-cell lung cancer [ICD-11: 2C25] REF00004300 Phase 2 DG01879 Melanoma [ICD-11: 2C30] REF00004300 Approved DG01883 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004564 Investigative DG01885 Discovery agent [ICD-11: N.A.] REF00003865 Approved DG01892 Squamous head and neck cell carcinom [ICD-11: 2D60] REF00004592 Approved DG01892 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004592 Phase 2 DG01892 Renal cell carcinoma [ICD-11: 2C90] REF00004592 Phase 1 DG01892 Gastric adenocarcinoma [ICD-11: 2B72] REF00004592 Investigative DG01892 Breast cancer [ICD-11: 2C60] REF00004592 Phase 1 DG01893 Hairy cell leukaemia [ICD-11: 2A82] REF00003922 Phase 2 DG01901 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004569 Approved DG01902 Solid tumour/cancer [ICD-11: 2A00-2F9Z] REF00004574 Phase 2 DG01902 Myelodysplastic syndrome [ICD-11: 2A37] REF00004574 Phase 2 DG01902 Haematological malignancy [ICD-11: 2B33] REF00004574 Phase 1 DG01902 Acute myeloid leukaemia [ICD-11: 2A60] REF00004574 Phase 1